UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON,~~Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30,~~March 31, ~~2023~~2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 0-21810

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)


Michigan		95-4318554
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
21680 Haggerty Road, Northville, MI		48167
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (248) 504-0500

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, no par value	THRM	Nasdaq

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At ~~October 20, 2023,~~April 25, 2024, there were ~~32,796,297~~31,644,934 issued and outstanding shares of Common Stock of the registrant.

GENTHERM INCORPORATED

TABLE OF CONTENTS




Part I. Financial Information			3
	Item 1.	Financial Statements (Unaudited)	3
		Consolidated Condensed Balance Sheets	3
		Consolidated Condensed Statements of Income	4
		Consolidated Condensed Statements of Comprehensive (Loss) Income	5
		Consolidated Condensed Statements of Cash Flows	6
		Consolidated Condensed Statements of Changes in Shareholders’ Equity	7
		Notes to Unaudited Consolidated Condensed Financial Statements	8
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2523
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3833
	Item 4.	Controls and Procedures	4035
Part II. Other Information			4136
	Item 1.	Legal Proceedings	4136
	Item 1A.	Risk Factors	4136
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4136
	Item 5.	Other Information	4136
	Item 6.	Exhibits	4237
Signatures			4338

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)


	September 30, 2023			December 31, 2022			March 31, 2024			December 31, 2023
ASSETS
Current Assets:
Cash and cash equivalents	$	154,354		$	153,891		$	125,107		$	149,673
Accounts receivable, net		263,765			247,131			265,149			253,579
Inventory:
Raw materials		122,919			136,217			134,463			126,013
Work in process		16,745			17,695			18,611			15,704
Finished goods		66,192			64,336			66,510			64,175
Inventory, net		205,856			218,248			219,584			205,892
Other current assets		76,651			64,597			90,592			78,420
Total current assets		700,626			683,867			700,432			687,564
Property and equipment, net		236,660			244,480			241,798			245,234
Goodwill		100,633			119,774			102,194			104,073
Other intangible assets, net		66,427			73,933			63,165			66,482
Operating lease right-of-use assets		27,442			29,945			34,631			27,358
Deferred income tax assets		73,177			69,840			81,395			81,930
Other non-current assets		20,632			17,461			29,095			21,730
Total assets	$	1,225,597		$	1,239,300		$	1,252,710		$	1,234,371
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	213,851		$	182,225		$	226,190		$	215,827
Current lease liabilities		7,633			7,143			7,642			7,700
Current maturities of long-term debt		620			2,443			324			621
Other current liabilities		90,199			93,814			98,939			100,805
Total current liabilities		312,303			285,625			333,095			324,953
Long-term debt, less current maturities		207,302			232,653			222,173			222,217
Non-current lease liabilities		16,451			20,538			23,126			16,175
Pension benefit obligation		3,165			3,638			2,768			3,209
Other non-current liabilities		26,324			24,573			24,489			23,095
Total liabilities	$	565,545		$	567,027		$	605,651		$	589,649
Shareholders’ equity:
Common Stock:
No par value; 55,000,000 shares authorized 32,795,093 and 33,202,082 issued and outstanding at September 30, 2023 and December 31, 2022, respectively		97,715			122,658
No par value; 55,000,000 shares authorized 31,629,224 and 31,542,001 issued and outstanding at March 31, 2024 and December 31, 2023, respectively								53,269			50,503
Paid-in capital		5,379			5,447			—			—
Accumulated other comprehensive loss		(55,955	)		(46,489	)		(45,195	)		(30,160	)
Accumulated earnings		612,913			590,657			638,985			624,379
Total shareholders’ equity		660,052			672,273			647,059			644,722
Total liabilities and shareholders’ equity	$	1,225,597		$	1,239,300		$	1,252,710		$	1,234,371

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2023			2022			2024			2023
Product revenues	$	366,195		$	332,962		$	1,102,143		$	861,334		$	356,015		$	363,625
Cost of sales		279,985			252,610			846,815			657,492			267,262			282,495
Gross margin		86,210			80,352			255,328			203,842			88,753			81,130
Operating expenses:
Net research and development expenses		23,150			22,666			72,991			62,425			22,745			25,145
Selling, general and administrative expenses		38,220			34,859			113,680			96,109			40,721			37,042
Impairment of goodwill		—			—			19,509			—
Restructuring expenses		1,099			6			3,412			561			7,238			1,269
Total operating expenses		62,469			57,531			209,592			159,095			70,704			63,456
Operating income		23,741			22,821			45,736			44,747			18,049			17,674
Interest (expense) income, net		(3,368	)		714			(9,444	)		(1,285	)
Interest expense, net														(3,244	)		(4,144	)
Foreign currency gain (loss)		2,107			(8,285	)		384			(1,516	)		2,549			(2,069	)
Other income		272			361			1,058			698			973			230
Earnings before income tax		22,752			15,611			37,734			42,644			18,327			11,691
Income tax expense		6,908			5,784			15,478			13,998			3,542			3,728
Net income	$	15,844		$	9,827		$	22,256		$	28,646		$	14,785		$	7,963
Basic earnings per share	$	0.48		$	0.30		$	0.67		$	0.87		$	0.47		$	0.24
Diluted earnings per share	$	0.48		$	0.29		$	0.67		$	0.86		$	0.47		$	0.24
Weighted average number of shares – basic		32,944			33,162			33,049			33,106			31,544			33,182
Weighted average number of shares – diluted		33,196			33,470			33,311			33,460			31,691			33,386

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2023			2022			2024			2023
Net income	$	15,844		$	9,827		$	22,256		$	28,646		$	14,785		$	7,963
Other comprehensive loss:
Other comprehensive (loss) income:
Pension benefit obligations		4			6			12			62			14			4
Foreign currency translation adjustments		(16,456	)		(28,682	)		(11,789	)		(60,676	)		(14,382	)		8,255
Unrealized (loss) gain on foreign currency derivative securities, net of tax		(2,090	)		1,273			2,311			1,490			(667	)		2,129
Unrealized loss on commodity derivative securities, net of tax		—			—			—			(5	)
Other comprehensive loss, net of tax		(18,542	)		(27,403	)		(9,466	)		(59,129	)
Other comprehensive (loss) income, net of tax														(15,035	)		10,388
Comprehensive (loss) income	$	(2,698	)	$	(17,576	)	$	12,790		$	(30,483	)	$	(250	)	$	18,351

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


	Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2024			2023
Operating Activities:
Net income	$	22,256		$	28,646		$	14,785		$	7,963
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization		38,531			30,470			13,818			13,583
Deferred income taxes		(3,017	)		(1,207	)		(184	)		(1,786	)
Stock based compensation		8,451			3,383			3,789			2,023
Loss on disposition of property and equipment		873			620			69			16
Provisions for inventory		6,597			4,293			296			1,704
Impairment of goodwill		19,509			—
Other		81			881			(842	)		(44	)
Changes in assets and liabilities:
Accounts receivable, net		(19,813	)		(55,780	)		(14,856	)		(8,237	)
Inventory		3,733			(53,223	)		(16,648	)		(1,137	)
Other assets		(19,218	)		(10,868	)		(29,226	)		(6,417	)
Accounts payable		32,158			60,983			12,337			24,289
Other liabilities		(10,099	)		4,759			6,340			(6,848	)
Net cash provided by operating activities		80,042			12,957
Net cash (used in) provided by operating activities								(10,322	)		25,109
Investing Activities:
Purchases of property and equipment		(26,526	)		(25,737	)		(11,320	)		(6,294	)
Proceeds from the sale of property and equipment		72			175			22			17
Acquisition of businesses, net of cash acquired		—			(224,097	)
Proceeds from deferred purchase price of factored receivables		10,139			2,168			2,732			3,728
Cost of technology investments		(630	)		(350	)		(265	)		—
Net cash used in investing activities		(16,945	)		(247,841	)		(8,831	)		(2,549	)
Financing Activities:
Borrowings on debt		—			207,000			10,000			—
Repayments of debt		(27,166	)		(11,559	)		(10,324	)		(564	)
Proceeds from the exercise of Common Stock options		263			1,556			812			263
Taxes withheld and paid on employees' share-based payment awards		(2,754	)		(5,415	)		(2,022	)		(2,667	)
Cash paid for the repurchase of Common Stock		(31,094	)		—			—			(9,997	)
Net cash (used in) provided by financing activities		(60,751	)		191,582
Net cash used in financing activities								(1,534	)		(12,965	)
Foreign currency effect		(1,883	)		(8,141	)		(3,879	)		3,144
Net cash increase (decrease) in cash and cash equivalents		463			(51,443	)
Net (decrease) increase in cash and cash equivalents								(24,566	)		12,739
Cash and cash equivalents at beginning of period		153,891			190,606			149,673			153,891
Cash and cash equivalents at end of period	$	154,354		$	139,163		$	125,107		$	166,630
Supplemental disclosure of cash flow information:
Cash paid for taxes	$	18,893		$	13,509		$	4,900		$	5,536
Cash paid for interest		9,737			3,334			3,310			3,235
Non-Cash Investing Activities:
Period-end balance of accounts payable for property and equipment	$	4,501		$	2,848		$	8,643		$	2,370
Deferred purchase price of receivables factored in the period	$	11,344		$	2,801			4,447			4,739

See accompanying notes to the consolidated condensed financial statements.

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands)

(Unaudited)


																												Accumulated
																												Other
																			Common Stock						Paid-in			Comprehensive			Accumulated
																			Shares			Amount			Capital			Loss			Earnings			Total
Balance at December 31, 2023																				31,542		$	50,503		$	—		$	(30,160	)	$	624,379		$	644,722
Net income																				—			—			—			—			14,785			14,785
Other comprehensive loss																				—			—			—			(15,035	)		—			(15,035	)
Stock compensation, net																				87			2,766			—			—			(179	)		2,587
Stock repurchase																				—			—			—			—			—			—
Balance at March 31, 2024																				31,629		$	53,269		$	—		$	(45,195	)	$	638,985		$	647,059


										Accumulated																		Accumulated
										Other																		Other
	Common Stock						Paid-in			Comprehensive			Accumulated						Common Stock						Paid-in			Comprehensive			Accumulated
	Shares			Amount			Capital			Loss			Earnings			Total			Shares			Amount			Capital			Loss			Earnings			Total
Balance at December 31, 2022		33,202		$	122,658		$	5,447		$	(46,489	)	$	590,657		$	672,273			33,202		$	122,658		$	5,447		$	(46,489	)	$	590,657		$	672,273
Net income		—			—			—			—			7,963			7,963			—			—			—			—			7,963			7,963
Other comprehensive income		—			—			—			10,388			—			10,388			—			—			—			10,388			—			10,388
Stock compensation, net		94			(241	)		(68	)		—			—			(309	)		94			(241	)		(68	)		—			—			(309	)
Stock repurchase		(169	)		(9,997	)		—			—			—			(9,997	)		(169	)		(9,997	)		—			—			—			(9,997	)
Balance at March 31, 2023		33,127		$	112,420		$	5,379		$	(36,101	)	$	598,620		$	680,318			33,127		$	112,420		$	5,379		$	(36,101	)	$	598,620		$	680,318
Net loss		—			—			—			—			(1,551	)		(1,551	)
Other comprehensive loss		—			—			—			(1,312	)		—			(1,312	)
Stock compensation, net		28			3,101			—			—			—			3,101
Stock repurchase		(167	)		(9,996	)		—			—			—			(9,996	)
Balance at June 30, 2023		32,988		$	105,525		$	5,379		$	(37,413	)	$	597,069		$	670,560
Net income		—			—			—			—			15,844			15,844
Other comprehensive loss		—			—			—			(18,542	)		—			(18,542	)
Stock compensation, net		2			3,291			—			—			—			3,291
Stock repurchase		(195	)		(11,101	)		—			—			—			(11,101	)
Balance at September 30, 2023		32,795		$	97,715		$	5,379		$	(55,955	)	$	612,913		$	660,052


										Accumulated
										Other
	Common Stock						Paid-in			Comprehensive			Accumulated
	Shares			Amount			Capital			Loss			Earnings			Total
Balance at December 31, 2021		33,008		$	118,646		$	5,866		$	(36,922	)	$	566,216		$	653,806
Net income		—			—			—			—			11,747			11,747
Other comprehensive loss		—			—			—			(8,806	)					(8,806	)
Stock compensation, net		119			(814	)		(146	)		—						(960	)
Balance at March 31, 2022		33,127		$	117,832		$	5,720		$	(45,728	)	$	577,963		$	655,787
Net income		—			—			—			—			7,072			7,072
Other comprehensive loss		—			—			—			(22,920	)		—			(22,920	)
Stock compensation, net		6			3,256			—			—			—			3,256
Balance at June 30, 2022		33,133		$	121,088		$	5,720		$	(68,648	)	$	585,035		$	643,195
Net income		—			—			—			—			9,827			9,827
Other comprehensive loss		—			—			—			(27,403	)		—			(27,403	)
Stock compensation, net		63			(1,287	)		(243	)		—			—			(1,530	)
Balance at September 30, 2022		33,196		$	119,801		$	5,477		$	(96,051	)	$	594,862		$	624,089

See accompanying notes to the consolidated condensed financial statements.

Note 1 – Overview

Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical ~~industries.~~patient temperature management. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, ~~valve~~fuel management valves and other valves for brake and engine systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the U.S., China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

During the first half of 2023, the Company launched Fit-for-Growth 2.0 to execute as part of our long-term growth strategy. Fit-for-Growth 2.0 is expected to deliver significant cost reductions through sourcing excellence, value engineering, manufacturing productivity, manufacturing footprint optimization, product profitability and cost synergies from the 2022 acquisition of Alfmeier Präzision SE. Additionally, the program is intended to drive operating expense efficiency to leverage scale.

Basis of Presentation and Significant Accounting Policies

The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2022.~~2023. The operating results for interim periods are not necessarily indicative of results that may be expected for ~~any~~ other interim ~~period~~periods or for the full year.

In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other ~~outside~~third-party sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

All amounts in these notes to the consolidated condensed financial statements are presented in thousands, except share and per share data.

Principles of Consolidation

The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in ~~entities~~affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in ~~entities~~affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

Variable Interest Entities

The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. In the first quarter of 2024, we recognized an increase in the fair value of our investment in Carrar of $1,097 in Other income in the consolidated condensed statements of income due to observable transactions. The Carrar investment was $~~5,700~~3,897 and $~~5,200~~2,800 as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, respectively, and is recorded in Other non-current assets in the consolidated condensed balance sheets.

Revenue Recognition

The Company has no material contract assets or contract liabilities as of ~~September 30, 2023.~~March 31, 2024.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $~~4,136~~10,945 and $~~2,239~~7,305 as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, respectively. These amounts are recorded in Other non-current assets in the consolidated condensed balance sheets and are being amortized into Product revenues in the consolidated condensed statements of income over the expected production life of the applicable program.

Note 2 – ~~Acquisitions~~New Accounting Pronouncements

~~Alfmeier Präzision SE~~

On ~~August 1, 2022, the Company acquired~~ ~~100~~% of the equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort.Recently Adopted Accounting Pronouncements

The ~~total consideration transferred was $170,700. The results~~Company considers the applicability and impact of ~~Alfmeier's operations are reported within~~all Accounting Standards Updates ("ASUs") issued by the ~~Automotive segment from the acquisition date.~~

~~The acquisition was accounted for as a business combination.~~ ~~The following table summarizes the final purchase consideration~~Financial Accounting Standards Board. New ASUs effective in 2023 were assessed and ~~estimated fair values of assets acquired and liabilities assumed as of the acquisition date:~~

Initial Allocation
as of
August 1, 2022

Measurement Period Adjustments

Final Allocation

Purchase price, cash consideration, net of cash acquired

$
164,887

$
5,813

$
170,700

—

Accounts receivable

24,988

(121
)

24,867

Inventory

36,026

417

36,443

Prepaid expenses and other assets

20,920

(74
)

20,846

Operating lease right-of-use assets

4,608

—

4,608

Property and equipment

89,942

1,242

91,184

Other intangible assets

22,668

8,791

31,459

Goodwill

43,678

(9,707
)

33,971

Assumed liabilities

(55,994
)

975

(55,019
)
Deferred tax liabilities

(21,949
)

4,290

(17,659
)
Net assets acquired

$
164,887

$
5,813

$
170,700

~~The following table summarizes the final allocation of the purchase consideration~~determined to ~~the other intangible assets acquired:~~

Final Fair Value

Weighted Average Life (in years)

Definite-lived:

Customer related

$
19,812

14

Technology

11,647

9

Total

$
31,459

Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable.

The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill isbe either not applicable or not expected to have a significant impact on the Company's consolidated condensed financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 requires a public entity to disclose, on an annual and interim basis, significant segment expenses that are included within each reported measure of segment profit or loss and regularly reviewed by the chief operating decision maker ("CODM"), the title and position of the CODM, clarification regarding the CODM's use of multiple measures of a segment's profit or loss in assessing segment performance (this must include a measure that is consistent with the measurement principles under U.S. GAAP, but may also include additional measures of a segment's profit or loss), and a description of the composition of amounts within an "Other" segment line item. Further, ASU 2023-07 requires that all annual disclosures about a reportable segment's profit or loss and assets currently required by Topic 280 to be ~~deductible~~provided in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 should be adopted retrospectively to all periods presented in the financial statements and early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-07 will have on the Company’s financial statement disclosures.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances income tax ~~purposes.~~disclosures to further disaggregate the effective tax rate reconciliation and income taxes paid. This update is effective for fiscal years beginning after December 15, 2024. ASU 2023-09 should be adopted prospectively, but retrospective application is permitted. Further, early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-09 will have on the Company’s financial statement disclosures.

~~The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022:~~

Three Months Ended September 30, 2022

Nine Months Ended September 30, 2022

Product revenues

$
352,877

$
1,004,974

Net income

9,033

21,330

~~Jiangmen Dacheng Medical Equipment Co. Ltd~~

On ~~July 13, 2022, the Company acquired~~ ~~100~~% of the equity interests of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng is a privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site.

~~The total consideration transferred was $35,048~~. The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $~~500. These cash payments were accounted for as compensation expense and recorded as a component of Selling, general and administrative expenses ratably over the service period.~~

~~The acquisition was accounted for as a business combination.~~ ~~The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date:~~

Initial Allocation
as of
July 13, 2022

Measurement Period Adjustments

Final Allocation

Purchase price, cash consideration, net of cash acquired

$
35,048

$
—

$
35,048

—

Accounts receivable

746

(124
)

622

Inventory

1,942

(177
)

1,765

Prepaid expenses and other assets

152

22

174

Operating lease right-of-use assets

841

—

841

Property and equipment

684

—

684

Other intangible assets

19,094

965

20,059

Goodwill

22,995

(3,464
)

19,531

Assumed liabilities

(2,799
)

(515
)

(3,314
)
Deferred tax liabilities

(8,607
)

3,293

(5,314
)
Net assets acquired

$
35,048

$
—

$
35,048

~~The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired:~~

Final Fair Value

Weighted Average Life (in years)

Definite-lived:

Customer related

$
12,837
��

12

Technology

4,749

12

Indefinite-lived:

Tradenames

2,473

—

Total

$
20,059

The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes.

~~The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.~~

Note 3 – Restructuring ~~and Impairments~~

The Company continuously monitors market developments, industry trends and changing customer needs and in response, has taken and may continue to undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs.

These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination.

2023 Manufacturing Footprint Rationalization

On September 19, 2023, the Company committed to a restructuring plan (“2023 Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this 2023 Plan, the Company ~~will relocate~~is in the process of relocating certain existing manufacturing and related activities in its Greenville, South Carolina facility to a new facility in Monterrey, Mexico.

The Company expects to incur total costs of between $~~14,000~~12,000 and $~~18,000~~16,000, of which between $~~13,000~~11,000 and $~~17,000~~15,000 are expected to be cash expenditures. The total expected costs include employee severance, retention and termination costs of between $2,000 and $4,000, capital expenditures of between $7,000 and $8,000 and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $1,000. The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $~~4,000~~2,000 and $~~5,000~~3,000. The actions under this 2023 Plan are expected to be substantially completed by the end of 2025. The actual timing, costs and savings of the 2023 Plan may differ materially from the Company’s current expectations and estimates.

During the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, the Company ~~did~~ recognized restructuring expense of $no747~~t recognize any material amounts~~ for employee separation costs and $293 for other costs.

The Company has recorded $1,737 of restructuring ~~expense.~~expenses since the inception of this program as of March 31, 2024.

Other Restructuring ~~Activities~~Actions

The Company has undertaken several discrete restructuring ~~actions.~~ actions in an effort to optimize its cost structure.

During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024, the Company’s Automotive segment recognized $4,219 for employee separation costs related to structural cost reductions impacting the Company’s global salaried workforce. These cost reductions are connected to Fit-for-Growth 2.0.

During the three months ended March 31, 2024, the Company’s Automotive segment recognized $1,805 for employee separation costs related to the relocation of electronic component manufacturing in Germany to a manufacturing facility in China.

During the three months ended March 31, 2024, the Company recognized $174 of other costs related to all other restructuring actions. These other restructuring actions are focused on the reduction of global overhead costs.

The Company expects to incur less than $1,000 of additional restructuring costs for the other restructuring actions that have been approved as of March 31, 2024.

During the three months ended March 31, 2023, the Company recognized $~~1,099~~1,256 ~~and $2,642, respectively,~~ for employee separation costs and $0164 ~~and $770, respectively, of other costs. During the three and nine months ended September 30, 2022, the Company recognized $~~0 ~~and $~~50~~, respectively, for employee separation costs and $~~6 ~~and $511, respectively,~~ for other costs. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs.

Restructuring Expenses By Reporting Segment

The following table summarizes restructuring expense for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ by reporting segment:

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Automotive

$
852

$
6

$
2,222

$
561

Medical

—

—

—

—

Corporate

247

—

1,190

—

Total

$
1,099

$
6

$
3,412

$
561


	Three Months Ended March 31,
	2024		2023
Automotive	$	7,114	$	1,074
Medical		20		—
Corporate		104		195
Total	$	7,238	$	1,269

Restructuring Liability

Restructuring liabilities are classified as ~~other~~Other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the ~~nine months ended September 30, 2023:~~

Employee Separation Costs

Other Related Costs

Total

Balance at December 31, 2022

$
588

$
—

$
588

Additions, charged to restructuring expenses

1,206

63

1,269

Cash payments

—

(63
)

(63
)
Currency translation

16

—

16

Balance at March 31, 2023

$
1,810

$
—

$
1,810

Additions, charged to restructuring expenses

337

707

1,044

Cash payments

(565
)

(707
)

(1,272
)
Currency translation

6

—

6

Balance at June 30, 2023

$
1,588

$
—

$
1,588

Additions, charged to restructuring expenses

1,099

—

1,099

Cash payments

(728
)

—

(728
)
Currency translation

(21
)

—

(21
)
Balance at September 30, 2023

$
1,938

$
—

$
1,938

~~Impairments~~

~~Non-Automotive Electronics Business~~

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $~~9,378, $5,601~~ ~~and $690~~ ~~for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.~~

~~During the three and nine months ended September 30, 2023, the Company recorded non-cash impairment charges of $3,426~~ ~~and $5,489, respectively, for the write down of inventory within the Automotive segment. These charges were recorded in Cost of sales.~~

~~The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.~~

~~Medical Segment~~

~~During the~~ three months ended ~~June 30, 2023, the Company determined that there were impairment indicators for its Medical reporting unit and conducted an impairment analysis, following which the Company concluded that $~~March 31, 2024:~~19,509~~ ~~of goodwill was impaired. Such non-cash impairment charge was recorded in Impairment of goodwill. See Note 5 for additional information about the goodwill impairment analysis.~~


	Employee Separation Costs			Other Related Costs			Total
Balance at December 31, 2023	$	2,150		$	—		$	2,150
Additions, charged to restructuring expenses		6,771			467			7,238
Cash payments		(1,762	)		(380	)		(2,142	)
Non-cash utilization		—			(87	)		(87	)
Currency translation		(19	)		—			(19	)
Balance at March 31, 2024	$	7,140		$	—		$	7,140

Note 4 – Details of Certain Balance Sheet Components


	September 30, 2023		December 31, 2022		March 31, 2024		December 31, 2023
Other current assets:
Billable tooling	$	13,748	$	15,267	$	17,939	$	16,877
Income tax and other tax receivable		14,042		15,041		17,847		16,017
Notes receivable		16,766		12,127		17,504		18,226
Prepaid expenses						11,391		7,889
Short-term derivative financial instruments		10,213		6,564		11,479		10,717
Prepaid expenses		9,503		6,239
Receivables due from factor		6,688		5,490		6,504		4,422
Other		5,691		3,869		7,928		4,272
Total other current assets	$	76,651	$	64,597	$	90,592	$	78,420
Other current liabilities:
Accrued employee liabilities	$	39,363	$	32,031	$	31,217	$	43,176
Liabilities from discounts and rebates		24,790		26,640		23,528		22,916
Income tax and other taxes payable		11,385		14,459		23,055		19,327
Restructuring						7,140		2,150
Accrued warranty		3,206		2,380		5,068		3,945
Restructuring		1,938		588
Other		9,517		17,716		8,931		9,291
Total other current liabilities	$	90,199	$	93,814	$	98,939	$	100,805

Note 5 – Goodwill and Other Intangibles

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, for the ~~nine~~three months ended ~~September 30, 2023~~March 31, 2024 was as follows:

Automotive

Medical

Total

Balance as of December 31, 2022

$
73,069

$
46,705

$
119,774

Impairment of goodwill

—

(19,509
)

(19,509
)
Currency translation and other

768

(400
)

368

Balance as of September 30, 2023

$
73,837

$
26,796

$
100,633


	Automotive			Medical			Total
Balance as of December 31, 2023	$	76,696		$	27,377		$	104,073
Currency translation and other		(1,543	)		(336	)		(1,879	)
Balance as of March 31, 2024	$	75,153		$	27,041		$	102,194

The Company’s cumulative goodwill impairment expense since inception was $19,509 as of March 31, 2024 and December 31, 2023, which includes Gentherm’s goodwill impairment of the Medical reporting unit in 2023.

Other Intangible Assets

Other intangible assets and accumulated amortization balances as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022~~2023 were as follows:


	September 30, 2023							December 31, 2022							March 31, 2024										December 31, 2023
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Accumulated Impairment			Net Carrying Value		Gross Carrying Value		Accumulated Amortization			Net Carrying Value
Definite-lived:
Customer relationships	$	110,845	$	(69,163	)	$	41,682	$	112,286	$	(65,748	)	$	46,538	$	112,931	$	(72,958	)	$	—		$	39,973	$	115,465	$	(73,737	)	$	41,728
Technology		44,042		(27,443	)		16,599		44,745		(25,709	)		19,036		44,871		(29,268	)		—			15,603		45,861		(29,317	)		16,544
Product development costs		18,389		(18,224	)		165		18,774		(18,456	)		318		18,868		(18,705	)		—			163		19,434		(19,270	)		164
Software development		1,007		—			1,007		1,007		—			1,007		1,007		(50	)		—			957		1,007		—			1,007
Indefinite-lived:
Tradenames		6,974		—			6,974		7,034		—			7,034		6,999		—			(530	)		6,469		7,039		—			7,039
Total	$	181,257	$	(114,830	)	$	66,427	$	183,846	$	(109,913	)	$	73,933	$	184,676	$	(120,981	)	$	(530	)	$	63,165	$	188,806	$	(122,324	)	$	66,482

AsIn addition to annual impairment testing, which is performed in the fourth quarter of ~~December 31, 2022,~~each fiscal year, the ~~estimated~~Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore would require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. During the three months ended March 31, 2024, we recorded a non-cash impairment charge of $530 for one of our tradenames within the Medical ~~reporting unit exceeded its carrying value by less than~~ 10~~%. During the second quarter~~segment. We are not presently aware of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicatedany other events or circumstances that would require us to revise the carrying value of ~~the reporting unit exceeded the fair value~~our assets or liabilities as of ~~the reporting unit, and accordingly an impairment expense was recorded for $19,509~~.

The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions.March 31, 2024.

Note 6 – Debt

The following table summarizes the Company’s debt as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022:~~2023:


	September 30, 2023						December 31, 2022						March 31, 2024						December 31, 2023
	Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
Revolving Credit Facility (U.S. Dollar denominations)		6.79	%	$	207,000			5.80	%	$	232,000			6.80	%	$	222,000			6.58	%	$	222,000
Other loans		3.90	%		247		3.89% - 5.21%				2,011			—			—			3.90	%		233
Finance leases		3.54	%		675			3.57	%		1,085			3.51	%		497			3.53	%		605
Total debt					207,922						235,096						222,497						222,838
Current maturities					(620	)					(2,443	)					(324	)					(621	)
Long-term debt, less current maturities				$	207,302					$	232,653					$	222,173					$	222,217

Credit Agreement

On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A., as administrative agent (the “Agent”).

The Second Amended and Restated Credit Agreement provides for a $500,000 secured revolving credit facility (the “Revolving Credit Facility”), with a $50,000 sublimit for swing line loans and a $15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company had no outstanding letters of credit issued as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022.~~2023.

Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $200,000. The Second Amended and Restated Credit Agreement matures on June 10, 2027.

The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders.

The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of ~~September 30, 2023,~~March 31, 2024, the Company was in compliance, in all material respects, with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable.

Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50%, Bank of America’s prime rate, or the Term SOFR rate plus 1.00%. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the ~~CME~~Chicago Mercantile Exchange with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175% to 0.300%, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility.

The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125% and 2.125%, respectively, for Term SOFR Rate Loans and 0.125% and 1.125%, respectively, for Base Rate Loans.

Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverage Ratio, $~~293,000~~278,000 remained available as of ~~September 30, 2023~~March 31, 2024 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies.

In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $~~1,417~~1,520, which have been capitalized and are being amortized into Interest expense, net over the term of the ~~credit facility.~~Revolving Credit Facility.

The scheduled principal maturities of our debt as of ~~September 30, 2023~~March 31, 2024 were as follows:


	U.S. Revolving Note		Other Debt		Total		U.S. Revolving Note		Other Debt		Total
2023	$	—	$	345	$	345
2024		—		365		365	$	—	$	324	$	324
2025		—		146		146		—		148		148
2026		—		66		66		—		68		68
2027		207,000		—		207,000		222,000		—		222,000
2028		—		—		—		—		—		—
2029								—		—		—
Total	$	207,000	$	922	$	207,922	$	222,000	$	540	$	222,540

Note 7 – Commitments and Contingencies

Legal and other contingencies

The Company ~~may be~~is subject to various legal actions and claims in the ordinary course of its business, ~~including~~which may include those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these

matters outstanding as of March 31, 2024 will not have a material adverse effect on its results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves.

Product Liability and Warranty Matters

~~In the event that~~Our products subject us to warranty claims and, from time to time product liability claims, based on the Company’s products ~~fail~~alleged failure to perform as expected or ~~result~~resulting in alleged bodily injury or property ~~damage, our products may subject us to warranty claims and product liability.~~damage. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims or liabilities in the future or that it will not incur significant costs to defend such claims.

The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims filed by customers, the warranty accrual is adjusted quarterly to reflect management’s estimate of future claims.

On February 14, 2024, the National Highway Traffic Safety Administration announced that Volkswagen Group of America, Inc. (“VW”) is recalling 261,257 vehicles from model years 2015-2020 to remedy an alleged problem with a suction jet pump seal inside the fuel tank system. VW informed Gentherm of its plan to conduct the recall on April 3, 2024. The suction jet pump is a product originally designed and manufactured by Alfmeier Präzision SE (“Alfmeier”), the business Gentherm acquired in August 2022. The Company has not accepted any financial responsibility for the recall and intends to provide replacement parts for the recall at commercial pricing paid by VW. The Company intends to pursue discussions with VW to advance its position and resolve this matter. No litigation has been threatened or filed as of the date of this report. If the Company is obligated to indemnify VW for the direct and indirect costs associated with the recall, such costs could be material. The Company has insurance policies that generally include coverage of the costs of a recall, although the Company’s costs related to manufacturing of replacement parts are generally not covered. In addition, the Company’s purchase agreement of Alfmeier includes indemnification provisions under which the Company believes it would have a claim against the sellers. Given the uncertainty that exists concerning the resolution of this matter, as of the date of this report, the Company cannot reasonably estimate the amount and timing of possible costs that may be incurred by the Company.

The following is a reconciliation of the changes in accrued warranty costs:


	Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2024			2023
Balance at the beginning of the period	$	2,380		$	1,916		$	3,945		$	2,380
Warranty opening balance from acquired entities		—			907
Warranty claims paid		(1,979	)		(890	)		(747	)		(559	)
Warranty expense for products shipped during the current period		3,311			1,963			806			988
Adjustments to warranty estimates from prior periods		(434	)		(200	)
Adjustments to warranty estimates from prior periods(a)								1,123			(6	)
Adjustments due to currency translation		(72	)		(106	)		(59	)		18
Balance at the end of the period	$	3,206		$	3,590		$	5,068		$	2,821

(a)

Change in estimate related to a claim received during the quarter ended March 31, 2024.

~~Other matters~~Note 8 – Supplier Finance Program

~~Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year~~The Company is party to ~~year. In addition, due~~a supplier finance program with a third-party service provider (“Service Provider”), pursuant to ~~supply shortages of semiconductors,~~which the Company has ~~entered into agreements~~offered the opportunity to participate to certain of the Company's suppliers. Although the program generally provides suppliers with ~~various~~a lower cost of capital than they could obtain individually due to the Company’s negotiated terms, the Company has no economic interest in a supplier’s participation and the Company has not pledged any assets to the Service Provider under this program.

Under this program, the Company and supplier initially agree on the contractual payment terms for the goods to be procured for the Company in the ordinary course. A supplier’s participation in this program is voluntary and does not impact its contractual payment terms with the Company, including the payment amount and timing of when payments are due. A participating supplier has the sole discretion to determine whether to sell one or more invoices, if any, to the Service Provider in exchange for payment by the Service Provider on an earlier date than provided for in the contract with the Company. Amounts due to participating suppliers are included in Accounts payable in the consolidated condensed balance sheets until the Company makes payment to ~~reserve~~ the ~~right~~Service Provider, even though the payment of such amount will be made to ~~purchase certain semiconductor chips over rolling periods of~~ 12-~~24 months, with volume commitments determined based on our anticipated production requirements.~~the supplier at an earlier date by the Service Provider. As of ~~September 30, 2023,~~March 31, 2024, the Company had outstanding payment obligations to participating suppliers of $9,473 confirmed under the program. Payments of the Company’s ~~total commitments for these semiconductor chip agreements was $25,603. Such agreements provide~~obligations to the ~~Company with priority access to semiconductor chips~~Service Provider are reported as ~~they become available, however, these agreements do not guarantee that our suppliers will meet~~operating cash flows in the ~~timing and quantities requested by Gentherm. All other purchase commitments as~~consolidated condensed statements of ~~September 30, 2023 were immaterial.~~cash flows.

Note 89 – Earnings Per Share

Basic earnings per share are computed by dividing net income by the weighted average number of shares of the Company’s Common Stock, no par value (“Common Stock”), outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents.

The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2023		2022		2023		2022		2024		2023
Net income	$	15,844	$	9,827	$	22,256	$	28,646	$	14,785	$	7,963

Basic weighted average shares of Common Stock outstanding		32,944,386		33,162,181		33,049,097		33,105,854		31,543,784		33,181,828
Dilutive effect of stock options, restricted stock awards and restricted stock units		251,614		308,258		261,504		353,896		147,547		204,306
Diluted weighted average shares of Common Stock outstanding		33,196,000		33,470,439		33,310,601		33,459,750		31,691,331		33,386,134

Basic earnings per share	$	0.48	$	0.30	$	0.67	$	0.87	$	0.47	$	0.24
Diluted earnings per share	$	0.48	$	0.29	$	0.67	$	0.86	$	0.47	$	0.24

Note 910 – Financial Instruments

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency ~~and copper commodity hedging~~ instruments, if any, to Cost of sales in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in Net cash (used in) provided by operating activities in the consolidated condensed statements of cash flows.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

The Company is party to a floating-to-fixed interest rate swap agreement ~~with a notional amount of $100,000~~ ~~and a maturity date of~~ ~~July 2025. This interest rate swap~~that is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility ~~borrowings that were drawn for the acquisitions of Alfmeier and Dacheng.~~borrowings. The periodic changes in fair value is recognized in Interest expense, net.

Information related to the recurring fair value measurement of derivative instruments in ~~our~~the consolidated condensed balance sheet as of ~~September 30, 2023~~March 31, 2024 is as follows:


				Asset Derivatives			Liability Derivatives								Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)		Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Assets/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	103,771	Other current assets	$	6,706	Other current liabilities	$	—	$	6,706	Level 2	$	74,122	Other current assets	$	9,113	Other current liabilities	$	—	$	9,113
Derivatives Not Designated as Hedging Instruments
Interest rate contracts	Level 2	$	100,000	Other current assets	$	3,506	Other current liabilities	$	—	$	3,506	Level 2	$	100,000	Other current assets	$	2,366	Other current liabilities	$	—	$	2,366

Information related to the recurring fair value measurement of derivative instruments in ~~our~~the consolidated condensed balance sheet as of December 31, ~~2022~~2023 is as follows:


				Asset Derivatives			Liability Derivatives								Asset Derivatives			Liability Derivatives
	Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Asset/ (Liabilities)		Fair Value Hierarchy	Notional Amount		Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value		Net Assets/ (Liabilities)
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Level 2	$	40,063	Other current assets	$	3,791	Other current liabilities	$	—	$	3,791	Level 2	$	101,109	Other current assets	$	8,655	Other current liabilities	$	—	$	8,655
Derivatives Not Designated as Hedging Instruments
Interest rate contracts	Level 2	$	100,000	Other current assets	$	2,772	Other current liabilities	$	—	$	2,772	Level 2	$	100,000	Other current assets	$	2,062	Other current liabilities	$	—	$	2,062

Information relating to the effect of derivative instruments on ~~our~~the consolidated condensed statements of income and the consolidated condensed statements of comprehensive (loss) income is as follows:


		Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	Location (Income/(Loss))	2023			2022			2023		2022			Location (Income/(Loss))	2024			2023
Derivatives Designated as Cash Flow Hedges
Foreign currency derivatives	Cost of sales – income	$	2,771		$	321		$	5,814	$	807		Cost of sales – income	$	3,376		$	1,059
	Other comprehensive income (loss)		(2,673	)		1,627			2,915		1,921		Other comprehensive income (loss)		(853	)		2,683
Total foreign currency derivatives		$	98		$	1,948		$	8,729	$	2,728			$	2,523		$	3,742

Commodity derivatives	Cost of sales – income	$	—		$	—		$	—	$	19
	Other comprehensive loss		—			—			—		(6	)
Total commodity derivatives		$	—		$	—		$	—	$	13

Derivatives Not Designated as Hedging Instruments
Foreign currency derivatives	Foreign currency gain	$	—		$	(4,288	)	$	—	$	(3,806	)
Total foreign currency derivatives		$	—		$	(4,288	)	$	—	$	(3,806	)

Interest rate contracts	Interest expense, net	$	62		$	3,191		$	734	$	2,498		Interest expense, net	$	304		$	(699	)
Total interest rate derivatives		$	62		$	3,191		$	734	$	2,498			$	304		$	(699	)

The Company did not incur any hedge ineffectiveness during the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 and ~~2022.~~2023.

Accounts Receivable Factoring

The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is considered an off-balance sheet arrangement to the Company

and is accounted for as a true sale and excluded from ~~accounts~~Accounts receivable in the consolidated condensed balance sheets. These factoring arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated condensed balance sheets. Cash proceeds received upon the sale of the receivables are included in Net cash (used in) provided by operating activities and the cash proceeds received on the deferred purchase price receivables are included in Net cash used in investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes.

Receivables factored and availability under receivables factoring agreements balances as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022~~2023 were as follows:


	September 30, 2023		December 31, 2022		March 31, 2024		December 31, 2023
Receivables factored and outstanding	$	22,372	$	19,108	$	16,510	$	18,532
Amount available under the credit limit		1,169		5,034		7,425		5,891
Collective factoring limit	$	23,541	$	24,142	$	23,935	$	24,423

Trade receivables sold and factoring fees incurred during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2023		2022(a)		2023		2022(a)		2024		2023
Trade receivables sold	$	35,115	$	23,706	$	111,915	$	23,706	$	30,102	$	38,540
Factoring fees incurred		221		64		588		64		179		161

~~(a)~~17

~~Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022)~~.

Note 1011 – Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative instruments (see Note 9)10) and pension plan assets, the Company had no material financial assets and liabilities that were carried at fair value at ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022.~~2023. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. ~~The~~During the year ended December 31, 2023, the Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for acquisitions ~~(see Note 2)~~ and goodwill of the Medical reporting ~~unit (see Note 5).~~unit. The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of ~~September 30, 2023,~~March 31, 2024, and December 31, ~~2022,~~2023, there were no other significant assets or liabilities measured at fair value on a non-recurring basis.

Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of ~~September 30, 2023,~~March 31, 2024, and December 31, ~~2022,~~2023, the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6).

Note 1112 – Equity

In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company iswas authorized to repurchase up to $150,000 of its issued and outstanding ~~common stock~~Common Stock over a three-year period, expiring December 15, 2023. On November 1, 2023, the Board of Directors extended the maturity date of the program from December 15, 2023 to June 30, 2024.

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, the Company ~~repurchased $11,101~~ ~~and $31,094, respectively, of shares~~did not make any repurchases under the 2020 Stock Repurchase ~~Program with an average price paid per share of $56.91~~ ~~and $58.54, respectively.~~Program. The 2020 Stock Repurchase Program had $~~98,906~~37,491 of repurchase authorization remaining as of ~~September 30, 2023.~~March 31, 2024.

Under the terms of the ASR Agreement, on November 2, 2023, the Company paid $60,000 to Bank of America for an initial purchase of approximately 1.22 million shares of Common Stock, representing 80% of ASR Repurchase Amount. The final settlement date is scheduled to occur in the second quarter of 2024. As of the final settlement date, Bank of America may be required to deliver additional shares of Common Stock to the Company or the Company may be required to deliver shares of Common Stock to Bank America, such that the Company’s repurchase of Common Stock under the ASR Agreement in aggregate will equal the ASR Repurchase Amount (based on the average of the daily volume-weighted average prices of the Common Stock during the term of the ASR Agreement, less a specified discount). There is no cash requirement as of the final settlement date.

The ASR Agreement contains provisions customary for agreements of this type, including the mechanisms to determine the number of shares of Common Stock that will be delivered at settlement, the required timing of delivery of the shares of Common Stock, the circumstances under which Bank of America is permitted to make adjustments to the transaction terms, the circumstances under which the ASR Agreement may be accelerated, extended or terminated early by Bank of America and specified representations and warranties of each party to the other party.

Note 1213 – Reclassifications Out of Accumulated Other Comprehensive Loss

Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ were as follows:


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Commodity Hedge Derivatives			Total			Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Total
Balance at June 30, 2023	$	(1,059	)	$	(43,602	)	$	7,248			$	—		$	(37,413	)
Balance at December 31, 2023																	$	(1,011	)	$	(34,830	)	$	5,681			$	(30,160	)
Other comprehensive (loss) income before reclassifications		—			(16,321	)		98				—			(16,223	)		—			(14,275	)		3,496				(10,779	)
Income tax effect of other comprehensive (loss) income before reclassifications		—			(135	)		(21	)			—			(156	)		—			(107	)		(762	)			(869	)
Amounts reclassified from accumulated other comprehensive loss into net income		5			—			(2,771	)	a		—	a		(2,766	)		21			—			(4,349	)	a		(4,328	)
Income taxes reclassified into net income		(1	)		—			604				—			603			(7	)		—			948				941
Net current period other comprehensive income (loss)		4			(16,456	)		(2,090	)			—			(18,542	)		14			(14,382	)		(667	)			(15,035	)
Balance at September 30, 2023	$	(1,055	)	$	(60,058	)	$	5,158			$	—		$	(55,955	)
Balance at March 31, 2024																	$	(997	)	$	(49,212	)	$	5,014			$	(45,195	)

(a)

The amounts reclassified from Accumulated other comprehensive loss were included in Cost of ~~sales.~~sales in the consolidated condensed statements of income.

2019

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at June 30, 2022

$
(2,837
)

$
(66,182
)

$
371

$
—

$
(68,648
)
Other comprehensive (loss) income before reclassifications

—

(28,411
)

1,948

—

(26,463
)
Income tax effect of other comprehensive (loss) income before reclassifications

—

(271
)

(423
)

—

(694
)
Amounts reclassified from accumulated other comprehensive loss into net income

6

—

(321
)
a

—

a

(315
)
Income taxes reclassified into net income

—

—

69

—

69

Net current period other comprehensive income (loss)

6

(28,682
)

1,273

—

(27,403
)
Balance at September 30, 2022

$
(2,831
)

$
(94,864
)

$
1,644

$
—

$
(96,051
)


	Defined Benefit Pension Plans			Foreign Currency Translation Adjustments			Foreign Currency Hedge Derivatives				Total
Balance at December 31, 2022	$	(1,067	)	$	(48,269	)	$	2,847			$	(46,489	)
Other comprehensive income before reclassifications		—			8,191			3,742				11,933
Income tax effect of other comprehensive income before reclassifications		—			64			(815	)			(751	)
Amounts reclassified from accumulated other comprehensive loss into net income		6			—			(1,059	)	a		(1,053	)
Income taxes reclassified into net income		(2	)		—			261				259
Net current period other comprehensive income		4			8,255			2,129				10,388
Balance at March 31, 2023	$	(1,063	)	$	(40,014	)	$	4,976			$	(36,101	)

(a)

The amounts reclassified from Accumulated other comprehensive loss were included in Cost of ~~sales.~~

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at December 31, 2022

$
(1,067
)

$
(48,269
)

$
2,847

$
—

$
(46,489
)
Other comprehensive (loss) income before reclassifications

—

(11,741
)

8,729

—

(3,012
)
Income tax effect of other comprehensive (loss) income before reclassifications

—

(48
)

(1,901
)

—

(1,949
)
Amounts reclassified from accumulated other comprehensive loss into net income

17

—

(5,814
)
a

—

a

(5,797
)
Income taxes reclassified into net income

(5
)

—

1,297

—

1,292

Net current period other comprehensive income (loss)

12

(11,789
)

2,311

—

(9,466
)
Balance at September 30, 2023

$
(1,055
)

$
(60,058
)

$
5,158

$
—

$
(55,955
)

~~(a)~~

~~The amounts reclassified from Accumulated other comprehensive loss were included~~sales in ~~Cost~~the consolidated condensed statements of ~~sales.~~

Defined
Benefit
Pension
Plans

Foreign
Currency
Translation
Adjustments

Foreign
Currency
Hedge
Derivatives

Commodity Hedge
Derivatives

Total

Balance at December 31, 2021

$
(2,893
)

$
(34,188
)

$
154

$
5

$
(36,922
)
Other comprehensive (loss) income before reclassifications

—

(60,023
)

2,728

13

(57,282
)
Income tax effect of other comprehensive (loss) income before reclassifications

—

(653
)

(606
)

(3
)

(1,262
)
Amounts reclassified from accumulated other comprehensive loss into net income

76

—

(807
)
a

(19
)
a

(750
)
Income taxes reclassified into net income

(14
)

—

175

4

165

Net current period other comprehensive income (loss)

62

(60,676
)

1,490

(5
)

(59,129
)
Balance at September 30, 2022

$
(2,831
)

$
(94,864
)

$
1,644

$
—

$
(96,051
)

~~(a)~~

~~The amounts reclassified from Accumulated other comprehensive loss were included in Cost of sales.~~income.

The Company expects that substantially all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of ~~September 30, 2023~~March 31, 2024 to be reclassified into earnings during the next twelve months. See Note 910 for additional information about derivative financial instruments and the effects from reclassification to Net income.

Note 1314 – Income Taxes

At the end of each interim period, the Company makes an estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs.

The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs.

A summary of the provision for income taxes and the corresponding effective tax rate for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023, ~~and 2022,~~ is shown below:


	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2023			2022			2024			2023
Income tax expense	$	6,908		$	5,784		$	15,478		$	13,998		$	3,542		$	3,728
Earnings before income tax	$	22,752		$	15,611		$	37,734		$	42,644		$	18,327		$	11,691
Effective tax rate		30.4	%		37.1	%		41.0	%		32.8	%		19.3	%		31.9	%

Income tax expense was $~~6,908~~3,542 for the three months ended ~~September 30, 2023~~March 31, 2024 on earnings before income tax of $~~22,752~~18,327, representing an effective tax rate of ~~30.4~~19.3%~~.The~~. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of a one-time benefit related to the Alfmeier acquisition, partially offset by income taxes on foreign earnings taxed at rates varying from the U.S. Federal statutory rate and the unfavorable impact of the global intangible low-tax income (“GILTI”)~~, partially offset by the impact of the release of accruals for uncertain tax positions.~~.

Income tax expense was $~~5,784~~3,728 for the three months ended ~~September 30, 2022~~March 31, 2023 on earnings before income tax of $~~15,611~~11,691, representing an effective tax rate of ~~37.1~~31.9%. The tax amount included the effect of the settlement and closure of a multi-year state audit of $454. Adjusted for the audit impacts, the effective rate was 28.0%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. Federal statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of ~~certain favorable tax effects of equity vesting.~~

~~Income tax expense was $15,478~~ ~~for the nine months ended September 30, 2023 on earnings before income tax of $37,734, representing an effective tax rate of~~ ~~41.0%. The pre-tax earnings included the effect of an impairment loss of $19,509~~ ~~with a tax benefit of $2,255. The effective tax rate differed from the U.S. Federal statutory rate of~~ 21~~% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate and the unfavorable impact of the GILTI, partially offset by the impact of~~ research and development credits in various jurisdictions and certain favorable tax effects ~~of equity vesting and the release of accruals for uncertain tax positions.~~

~~Income tax expense was $13,998~~ ~~for the nine months ended September 30, 2022~~ on ~~earnings before income tax of $42,644, representing an effective tax rate of~~ ~~32.8%. The effective tax rate differed from the U.S. Federal statutory rate of~~ ~~21.0~~% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects of equitystock compensation vesting.

Note 1415 – Segment Reporting

Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

•

Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, lumbar and massage comfort solutions, ~~valve~~fuel management valves and other valves for brake and engine systems, ~~battery performance solutions,~~ and automotive electronic and software systems.

•

Medical – this segment represents the results from our patient temperature management business within the medical industry.

The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment.

The tables below present segment information about the reported Product revenues, Depreciation and amortization and Operating income (loss) of the Company for the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 and ~~2022.~~2023.


Three Months Ended September 30,	Automotive		Medical			Corporate			Total
Three Months Ended March 31,											Automotive		Medical			Corporate			Total
2024
Product revenues											$	344,638	$	11,377		$	—		$	356,015
Depreciation and amortization												12,408		883			527		$	13,818
Operating income (loss)												43,210		(483	)		(24,678	)	$	18,049
2023
Product revenues	$	354,782	$	11,413		$	—		$	366,195	$	352,692	$	10,933		$	—		$	363,625
Depreciation and amortization		11,399		882			173		$	12,454		12,340		978			265		$	13,583
Operating income (loss)		41,690		(805	)		(17,144	)	$	23,741		38,379		(493	)		(20,212	)	$	17,674
2022
Product revenues	$	322,555	$	10,407		$	—		$	332,962
Depreciation and amortization		10,499		1,035			302		$	11,836
Operating income (loss)		43,067		(2,232	)		(18,014	)	$	22,821

Nine Months Ended September 30,	Automotive		Medical			Corporate			Total
2023
Product revenues	$	1,069,007	$	33,136		$	—		$	1,102,143
Depreciation and amortization		34,910		2,756			865		$	38,531
Operating income (loss)		126,630		(21,838	)		(59,056	)	$	45,736
2022
Product revenues	$	829,570	$	31,764		$	—		$	861,334
Depreciation and amortization		27,333		2,224			913		$	30,470
Operating income (loss)		98,367		(3,264	)		(50,356	)	$	44,747

Automotive and Medical segment Product revenues by product category for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ were as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

2023

2022

2023

2022

Climate Control Seat

$
124,905

$
112,059

$
360,868

$
311,281

Seat Heaters

77,238

75,568

231,132

210,367

Steering Wheel Heaters

39,861

31,482

115,166

89,169

Lumbar and Massage Comfort Solutions (a)

33,260

22,740

109,602

22,740

Valve Systems (a)

27,830

18,542

82,516

18,542

Automotive Cables

19,668

18,338

60,131

59,662

Battery Performance Solutions

17,242

20,331

57,138

55,395

Electronics

10,163

12,083

30,456

33,190

Other Automotive

4,615

11,412

21,998

29,224

Subtotal Automotive segment

354,782

322,555

1,069,007

829,570

Medical segment (b)

11,413

10,407

33,136

31,764

Total Company

$
366,195

$
332,962

$
1,102,143

$
861,334

~~(a)~~

~~Represents Product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2)~~


	Three Months Ended March 31,
	2024		2023
Climate Control Seat	$	115,590	$	114,753
Seat Heaters		77,076		75,636
Steering Wheel Heaters		39,814		36,347
Lumbar and Massage Comfort Solutions		38,251		38,738
Valve Systems		26,625		26,994
Automotive Cables		21,519		20,220
Battery Performance Solutions		13,608		20,309
Electronics		8,185		10,970
Other Automotive		3,970		8,725
Subtotal Automotive segment		344,638		352,692
Medical segment		11,377		10,933
Total Company	$	356,015	$	363,625

~~(b)~~21

~~Includes Product revenues of $1,988~~

~~and $4,939~~ ~~for the three and nine months ended September 30, 2023, respectively, and $1,234~~ ~~for the three and nine months ended September 30, 2022 from Dacheng (acquired on July 13, 2022) - (see Note 2)~~

Total Product revenues information by geographic area for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023 ~~and 2022~~ is as follows (based on shipment destination):


	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended March 31,
	2023		2022		2023		2022		2024		2023
United States	$	134,588	$	131,021	$	414,359	$	337,759	$	125,453	$	141,452
China		61,004		57,439		161,530		127,183		54,476		46,654
South Korea		27,369		22,751		86,102		67,632		28,184		28,738
Germany		24,456		19,454		77,007		54,805		23,613		26,512
Czech Republic		16,684		13,247		51,706		35,630		19,584		17,650
Japan		16,906		17,603		44,995		42,305
Romania		13,828		11,592		39,797		35,866		14,222		12,533
Slovakia		10,946		8,109		35,254		25,755		13,178		11,596
Japan										12,455		15,222
United Kingdom										11,324		10,133
Mexico		15,251		7,062		34,701		16,171		10,015		9,094
Finland		8,286		9,757		29,558		26,244
Other		36,877		34,927		127,134		91,984		43,511		44,041
Total Non-U.S.		231,607		201,941		687,784		523,575		230,562		222,173
Total Company	$	366,195	$	332,962	$	1,102,143	$	861,334	$	356,015	$	363,625

2422

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as: the expected light vehicle production in the Company’s key markets; the integration of acquisitions; the impact of macroeconomic and geopolitical conditions; the ~~potential impact of ongoing and future labor strikes among certain original equipment manufacturers (“OEMs”) and suppliers; the~~ components of and our ability to execute our updated strategic plan and 2023 manufacturing footprint rationalization restructuring plan; long-term consumer and technological trends in the ~~Automotive~~automotive industry and our related market opportunity for our existing and new products and technologies; the competitive landscape; the impact of global tax reform legislation; the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs; and our ability to finance sufficient working capital. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s reasonable expectations and beliefs. In making these statements we rely on assumptions and analysis based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we consider appropriate under the circumstances. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 and subsequent reports filed with or furnished to the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, with reasonable frequency, we have entered into business combinations, acquisitions, divestitures, strategic investments and other significant transactions. Such forward-looking statements do not include the potential impact of any such transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, ~~our~~the consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, ~~2022.~~2023.

Overview

Gentherm Incorporated is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical ~~industries.~~patient temperature management. Automotive products include variable temperature Climate Control ~~Seats,~~Seats® (“CCS”), heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, ~~valve~~fuel management valves and other valves for brake and engine systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major ~~OEMs~~original equipment manufacturers ("OEMs") operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the U.S., China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

Our Automotive sales are driven by the number of vehicles produced by the OEMs, which is ultimately dependent on consumer demand for automotive vehicles, our product content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. Historically, new vehicle demand and product content (i.e. vehicle features) have been driven by macroeconomic and other factors, such as interest rates, automotive manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Vehicle content has also been driven by trends in consumer preferences, such as preferences for smart devices and features, personalized user experience, and comfort, health and wellness. Economic volatility or weakness in North America, Europe or Asia, as well as global geopolitical factors, have had and could result in a significant reduction in automotive sales and production by our customers, which have had and would have an adverse effect on our business, results of operations and financial condition. We believe our diversified OEM customer base and

geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns

and benefit from industry upturns in the ordinary course. However, shifts in the mix of global automotive production to higher cost regions or to vehicles that contain less of our product content as well as continuing production challenges and inflationary pressures ~~could~~have adversely ~~impact~~impacted our ~~profitability.~~profitability and may continue to do so. In addition, we have been and may in the future be adversely impacted by volatility or weakness in markets for hybrid or electric vehicles specifically. We believe our products offer certain advantages for hybrid and electric vehicles, including improved energy efficiency, and position us well to withstand changes in the volume mix between vehicles driven by internal combustion engines and hybrid and other electric vehicles. We believe our industry is increasingly progressing towards a focus on human comfort and health and wellness, which is evidenced by increasing adoption rates for comfort products. We believe that products we are developing, such as ClimateSense®, WellSense™, and our acquisition of Alfmeier’s pneumatic comfort solutions, position us well to address trends in consumer preferences such as personalized user experience, comfort, health and wellness. Gentherm is an independent partner that can cooperate with any combination of the vehicle OEMs and seat manufacturers globally, including those that are vertically integrated, to create innovative and unique configurations that adapt to industry trends.

Recent Trends

Global Conditions

Since 2020, the global economy has experienced significant volatility and supply chain disruption, which has had a widespread adverse effect on the global automotive industry. These macroeconomic conditions have resulted in fluctuating demand and production disruptions, facility closures, labor shortages and work stoppages. In addition, global inflation has increased significantly beginning in 2021. ~~Rising~~Although supply chain conditions have steadily improved and certain inflationary pressures have moderated, rising costs of materials, labor, equipment and other inputs used to manufacture and sell our products, including freight and logistics costs, have impacted, and may in the future impact, operating costs and operating results. We continue to employ measures to mitigate the impact of cost increases through identification of sourcing and manufacturing efficiencies where possible. However, we have been unable to fully mitigate or pass through the increases in our operating costs, which may continue in the future.

~~The direct~~We are exposed to foreign currency risk due to the translation and ~~indirect impacts~~remeasurement of the results of certain international operations. Therefore, fluctuations in foreign currency exchange rates can create volatility in the results of operations and may adversely affect our financial condition.

We have a global manufacturing footprint that enables us to serve our customers in the regions they operate and shift production between regions to remain competitive. In recent years there have been various ongoing geopolitical conflicts, such as the current conflicts between Russia and Ukraine, and in the Middle East, heightened tensions in the Red Sea, and potential tensions in the South China Sea. These conflicts have interrupted ocean freight shipping and if prolonged or intensified, could have a substantial adverse effect on our ~~markets,~~financial results. We, like other manufacturers, have a high proportion of fixed structural costs, and therefore relatively small changes in industry vehicle production can have a substantial effect on our financial results. If industry vehicle sales were to decline to levels significantly below our planning assumption, the decline could have a substantial adverse effect on our financial condition, results of operations, and financial performance remain unpredictable. As a result of this continued uncertainty, there may still be impacts on our industry, operations, workforce, supply chains, distribution systems, and demand for our products in the future which cannot be reasonably estimated at this time.

Beginning in the third quarter of 2023 and continuing into the fourth quarter, several North American OEMs have experienced union-led labor strikes at certain of their facilities. As the automotive industry relies heavily on “just-in-time” delivery of components, these strikes have led to labor shortages, work stoppages and other related disruptions, which have limited and continue to limit purchases of our products. During the three and nine months ended September 30, 2023, we experienced an insignificant impact on product revenues resulting from the labor strikes. We estimate that if the current strike actions known as of October 25, 2023, were to continue to be idled through the end of November, it would result in approximately $15 million to $20 million of revenue loss for Gentherm in the fourth quarter of 2023. On October 25, 2023, it was announced that a tentative agreement was reached between union leaders and Ford. Ford represents approximately 25-30% of the impact of the estimated Gentherm revenue loss in the fourth quarter. If the labor strikes are prolonged or expanded, they would have further adverse effects on our business and financial results, and may result in the temporary shutdown of the related Gentherm production facilities.”cash flow.

On December 15, 2022, the European Union (“EU”) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development Pillar Two Framework. The effective dates for different aspects of the directive are January 1, 2024, and January 1, 2025. The aspects of the directive that were effective as of January 1, 2024 did not have a material impact on the Company’s financial statements. Further, the Company does not expect the remaining aspects to have a material impact to the Company’s financial statements. The Company will continue to evaluate the potential impact on future periods of these tax regulations.

Fit-for-Growth 2.0

During the first half of 2023, wethe Company launched Fit-for-Growth 2.0 to execute as part of our long-term ~~strategy that includes a profitability improvement initiative with a plan to achieve high teens Adjusted EBITDA margin rate by 2026.~~growth strategy. Fit-for-Growth 2.0 is expected to deliver significant cost reductions through sourcing excellence, value engineering, manufacturing productivity, manufacturing footprint optimization, ~~value engineering, sourcing excellence~~product profitability and cost synergies from the Alfmeier acquisition. Additionally, the program is intended to drive operating expense efficiency to leverage ~~scale as we continue our growth path towards our target of over $2 billion dollars by 2026.~~scale.

~~Acquisitions~~24

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm

Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site. The total consideration transferred was $35.0 million.

On August 1, 2022, the Company acquired 100% of the equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned well with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration for this acquisition was $170.7 million.

~~See Note 2, “Acquisitions” to the consolidated condensed financial statements included in this Report for additional information.~~

~~Impairments – Non-Automotive Electronics Business~~

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $9.4 million, $5.6 million and $0.7 million for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.

During the three and nine months ended September 30, 2023, the Company recorded non-cash impairment charges of $3.4 million and $5.5 million for the write down of inventory within the Automotive segment. This charge is recorded in Cost of sales.

~~The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.~~

~~Impairments - Medical Segment~~

As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10%. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value, and accordingly an impairment expense was recorded for $19.5 million.

The primary factors leading to the decline in value from the analysis performed at December 31, 2022 were a reduction in expected future cash flows, due to the Company re-evaluating our forecasted results and an increase in the discount rate which is based on the Medical reporting unit’s weighted average cost of capital. The decline in expected future cash flows resulted primarily from a reduction of forecasted revenue growth rates. If the Company’s revised expectation of revenue growth is not achieved or if the estimated growth rates are reduced because of new information or experience, the fair value of the Medical reporting unit could decrease, which could result in further impairment of goodwill.

2023 Manufacturing Footprint Rationalization

On September 19, 2023, the Company committed to a restructuring plan (“2023 Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this 2023 Plan, the Company will relocate certain existing manufacturing and related activities in its Greenville, South Carolina facility to a new facility in Monterrey, Mexico.

The Company expects to incur total costs of between ~~$14~~$12 million and ~~$18~~$16 million, of which between ~~$13~~$11 million and ~~$17~~$15 million are expected to be cash expenditures. The actions under the 2023 Plan are expected to be substantially completed by the end of 2025 and generate annual benefits of between $5 million and $6 million. The actual timing, costs and savings of the 2023 Plan may differ materially from the Company’s current expectations and estimates. During the three months ended March 31, 2024, the Company recognized restructuring expense of $0.7 million for employee separation costs and $0.3 million for other costs.

See Note 3, “Restructuring, ~~and Impairments”~~” to the notes to the consolidated condensed financial statements included in this Report for additional ~~information.~~information related to this plan.

Light Vehicle Production Volumes

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact

production by us, our supply chain and our customers. According to the forecasting firm S&P Global Mobility ~~(October 2023~~(April 2024 release), global light vehicle production in the three ~~and nine~~ months ended ~~September 30, 2023~~March 31, 2024 in the Company’s key markets of North America, Europe, China, Japan and Korea, as compared to the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, are shown below (in millions of units):


	Three Months Ended September 30,							Nine Months Ended September 30,							Three Months Ended March 31,
	2023		2022		% Change			2023		2022		% Change			2024		2023		% Change
North America		4.0		3.6		9.3	%		12.0		10.7		11.3	%		3.9		3.9		1.4	%
Europe		3.9		3.6		6.3	%		13.1		11.5		14.0	%		4.5		4.6		(2.5	)%
Greater China		7.4		7.4		(0.3	)%		20.0		19.1		4.8	%		6.2		5.9		4.4	%
Japan / South Korea		3.1		2.8		8.8	%		9.4		8.0		16.8	%		2.9		3.2		(9.7	)%
Total light vehicle production volume in key markets		18.3		17.5		4.6	%		54.5		49.4		10.3	%		17.5		17.6		(0.6	)%

The S&P Global Mobility ~~(October 2023~~(April 2024 release) forecasted light vehicle production volume in the Company’s key markets for full year ~~2023~~2024 to ~~increase to 73.5~~remain flat at 75.4 million units ~~an 8.6% increase~~ from full year ~~2022~~2023 light vehicle production volumes. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, these forecasts generally are updated monthly, and future forecasts have been and may continue to be significantly different from period to period due to changes in macroeconomic and geopolitical conditions or matters specific to the automotive industry. Further, due to differences in regional product mix at our manufacturing facilities, as well as material production schedules from our customers for our products on specific vehicle programs, our future forecasted results do not directly correlate with the global and/or regional light vehicle production forecasts of S&P Global Mobility or other third-party sources.

Automotive New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the ~~third~~first quarter of ~~2023,~~2024, we secured new automotive business awards totaling ~~$520 million, bringing the year-to-date total as of September 30, 2023 to $1.7 billion. Also, through the date of this filing we have reached a year-to-date total of $2 billion.~~$530 million. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by our customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that automotive new business awards are an indicator of future revenue. ~~New~~Automotive new business awards are not projections of revenue or future business as of ~~September 30, 2023,~~March 31, 2024, the date of this Report or any other date. Customer projections regularly change over time, and we do not update our calculation of any automotive new business award after the date initially communicated. Automotive new business awards in the ~~third~~first quarter ~~2023~~2024 also do not reflect, in particular, the impact of macroeconomic and geopolitical challenges ~~or the labor strikes~~ on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties that are included in this Report or incorporated by reference in “Forward-Looking Statements” above.

Stock Repurchase Program

In December 2020, the Board of Directors authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding Common Stock, no par value (“Common Stock”) over a three-year period, expiring December 15, 2023. On November 1, 2023, the Board of Directors extended the maturity date of the program from December 15, 2023 to June 30, 2024. Repurchases under the 2020 Stock Repurchase Program may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the three ~~and nine~~ months ended ~~September 30, 2023,~~March 31, 2024, the Company ~~repurchased $11.1 million and $31.1 million, respectively, of shares~~did not make any repurchases under the 2020 Stock Repurchase ~~Program with an average price paid per share of $56.91 and $58.54, respectively.~~Program. The 2020 Stock Repurchase Program had ~~$98.9~~$37.5 million repurchase authorization remaining as of ~~September 30, 2023.~~March 31, 2024.

On November 1, 2023, following the above-noted extension, the Company entered into a Confirmation of Issuer Forward Repurchase Transaction agreement (the “ASR Agreement”) with Bank of America, N.A. (“Bank of America”) that provides for the Company to purchase shares of Common Stock in an aggregate amount of $60 million (“ASR Repurchase Amount”) under the 2020 Stock Repurchase Program. Under the terms of the ASR Agreement, on November 2, 2023, the Company paid $60 million to Bank of America for an initial purchase of approximately 1.22 million shares of Common Stock, representing 80% of ASR Repurchase Amount. The final settlement date is scheduled to occur in the second quarter of 2024. As of the final settlement date, Bank of America may be required to deliver additional shares of Common Stock to the Company or the Company may be required to deliver shares of Common Stock to Bank America, such that the Company’s repurchase of Common Stock under the ASR Agreement in aggregate will equal the ASR Repurchase Amount (based on the average of the daily volume-weighted average prices of the Common Stock during the term of the ASR Agreement, less a specified discount). There is no cash requirement as of the final settlement date. For further information regarding the ASR Agreement, see Note 12, "Equity," to the notes to the consolidated condensed financial statements included in this Report.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.

See Note ~~14,~~15, “Segment ~~Reporting”~~Reporting,” to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income. The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

Consolidated Results of Operations

The results of operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023, ~~and 2022,~~ in thousands, were as follows:


	Three Months Ended September 30,									Nine Months Ended September 30,									Three Months Ended March 31,
	2023			2022			Favorable / (Unfavorable)			2023			2022			Favorable / (Unfavorable)			2024			2023			Favorable / (Unfavorable)
Product revenues	$	366,195		$	332,962		$	33,233		$	1,102,143		$	861,334		$	240,809		$	356,015		$	363,625		$	(7,610	)
Cost of sales		279,985			252,610			(27,375	)		846,815			657,492			(189,323	)		267,262			282,495			15,233
Gross margin		86,210			80,352			5,858			255,328			203,842			51,486			88,753			81,130			7,623
Operating expenses:
Net research and development expenses		23,150			22,666			(484	)		72,991			62,425			(10,566	)		22,745			25,145			2,400
Selling, general and administrative expenses		38,220			34,859			(3,361	)		113,680			96,109			(17,571	)		40,721			37,042			(3,679	)
Impairment of goodwill		—			—			—			19,509			—			(19,509	)
Restructuring expenses		1,099			6			(1,093	)		3,412			561			(2,851	)		7,238			1,269			(5,969	)
Total operating expenses		62,469			57,531			(4,938	)		209,592			159,095			(50,497	)		70,704			63,456			(7,248	)
Operating income		23,741			22,821			920			45,736			44,747			989			18,049			17,674			375
Interest (expense) income, net		(3,368	)		714			(4,082	)		(9,444	)		(1,285	)		(8,159	)
Interest expense, net																				(3,244	)		(4,144	)		900
Foreign currency gain (loss)		2,107			(8,285	)		10,392			384			(1,516	)		1,900			2,549			(2,069	)		4,618
Other income		272			361			(89	)		1,058			698			360			973			230			743
Earnings before income tax		22,752			15,611			7,141			37,734			42,644			(4,910	)		18,327			11,691			6,636
Income tax expense		6,908			5,784			(1,124	)		15,478			13,998			(1,480	)		3,542			3,728			186
Net income	$	15,844		$	9,827		$	6,017		$	22,256		$	28,646		$	(6,390	)	$	14,785		$	7,963		$	6,822

Product revenues by product category, in thousands, for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2024 and 2023, ~~and 2022,~~ were as follows:


	Three Months Ended September 30,										Nine Months Ended September 30,										Three Months Ended March 31,
	2023		2022		$ Change			% Change			2023		2022		$ Change			% Change			2024		2023		$ Change			% Change
Climate Control Seat	$	124,905	$	112,059	$	12,846			11.5	%	$	360,868	$	311,281	$	49,587			15.9	%	$	115,590	$	114,753	$	837			0.7	%
Seat Heaters		77,238		75,568		1,670			2.2	%		231,132		210,367		20,765			9.9	%		77,076		75,636		1,440			1.9	%
Steering Wheel Heaters		39,861		31,482		8,379			26.6	%		115,166		89,169		25,997			29.2	%		39,814		36,347		3,467			9.5	%
Lumbar and Massage Comfort Solutions		33,260		22,740		10,520			46.3	%		109,602		22,740		86,862			382.0	%		38,251		38,738		(487	)		(1.3	)%
Valve Systems		27,830		18,542		9,288			50.1	%		82,516		18,542		63,974			345.0	%		26,625		26,994		(369	)		(1.4	)%
Automotive Cables		19,668		18,338		1,330			7.3	%		60,131		59,662		469			0.8	%		21,519		20,220		1,299			6.4	%
Battery Performance Solutions		17,242		20,331		(3,089	)		(15.2	)%		57,138		55,395		1,743			3.1	%		13,608		20,309		(6,701	)		(33.0	)%
Electronics		10,163		12,083		(1,920	)		(15.9	)%		30,456		33,190		(2,734	)		(8.2	)%		8,185		10,970		(2,785	)		(25.4	)%
Other Automotive		4,615		11,412		(6,797	)		(59.6	)%		21,998		29,224		(7,226	)		(24.7	)%		3,970		8,725		(4,755	)		(54.5	)%
Subtotal Automotive segment		354,782		322,555		32,227			10.0	%		1,069,007		829,570		239,437			28.9	%		344,638		352,692		(8,054	)		(2.3	)%
Medical segment		11,413		10,407		1,006			9.7	%		33,136		31,764		1,372			4.3	%		11,377		10,933		444			4.1	%
Total Company	$	366,195	$	332,962	$	33,233			10.0	%	$	1,102,143	$	861,334	$	240,809			28.0	%	$	356,015	$	363,625	$	(7,610	)		(2.1	)%

Product Revenues

Below is a summary of our product revenues, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended September 30,

Variance Due To:

2023

2022

Favorable /
(Unfavorable)

Automotive Volume

FX

Acquisitions

Pricing / Other

Total

Product revenues

$
366,195

$
332,962

$
33,233

$
19,621

$
4,825

$
18,866

$
(10,079
)

$
33,233


	Three Months Ended March 31,							Variance Due To:
	2024		2023		Favorable / (Unfavorable)			Automotive Volume			FX			Pricing / Other			Total
Product revenues	$	356,015	$	363,625	$	(7,610	)	$	(1,671	)	$	(2,797	)	$	(3,142	)	$	(7,610	)

Product revenues for the three months ended ~~September 30, 2023 increased 10.0%~~March 31, 2024 decreased 2.1% as compared to the three months ended ~~September 30, 2022.~~March 31, 2023. The ~~increase~~decrease in product revenues is due to favorable volumes in several product lines within the Automotive segment, favorable foreign currency impacts primarily attributable to the Euro and the Korean Won, and the inclusion of sales from Alfmeier and Dacheng since the acquisitions, partially offset by unfavorable pricing, ~~other, and unfavorable foreign currency impacts primarily attributable to the Chinese Renminbi.~~

~~Below is a summary of our product revenues, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

Variance Due To:

2023

2022

Favorable /
(Unfavorable)

Automotive Volume

FX

Acquisitions

Pricing / Other

Total

Product revenues

$
1,102,143

$
861,334

$
240,809

$
105,363

$
(4,962
)

$
152,844

$
(12,436
)

$
240,809

Product revenues for the nine months ended September 30, 2023 increased 28.0% as compared to the nine months ended September 30, 2022. The increase in product revenues is due to favorable volumes in several product lines within the Automotive segment, favorable foreign currency impacts primarily attributable to the Euro, and the inclusion of sales from Alfmeier and Dacheng since the acquisitions, partially offset by lower cost recoveries from customers, ~~and~~ unfavorable foreign currency impacts primarily attributable to the Chinese Renminbi ~~the~~and Korean Won, and unfavorable automotive volumes, partially offset by favorable foreign currency impacts primarily attributable to the ~~Japanese Yen.~~Euro.

Cost of Sales

Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:


	Three Months Ended September 30,									Variance Due To:														Three Months Ended March 31,								Variance Due To:
	2023			2022			Favorable / (Unfavorable)			Automotive Volume			Operational Performance		FX			Acquisitions and Other			Total			2024			2023			Favorable / (Unfavorable)		Automotive Volume			Operational Performance		FX			Other			Total
Cost of sales	$	279,985		$	252,610		$	(27,375	)	$	(11,981	)	$	14,320	$	(6,508	)	$	(23,206	)	$	(27,375	)	$	267,262		$	282,495		$	15,233	$	553		$	18,200	$	(892	)	$	(2,628	)	$	15,233
Gross margin	$	86,210		$	80,352		$	5,858		$	7,640		$	10,218	$	(1,683	)	$	(10,317	)	$	5,858		$	88,753		$	81,130		$	7,623	$	(1,118	)	$	16,900	$	(3,689	)	$	(4,470	)	$	7,623
Gross margin - Percentage of product revenues		23.5	%		24.1	%																			24.9	%		22.3	%

Cost of sales for the three months ended ~~September 30, 2023 increased 10.8%~~March 31, 2024 decreased 5.4% as compared to the three months ended ~~September 30, 2022.~~March 31, 2023. The ~~increase~~decrease in cost of sales is primarily due to ~~increased~~lower material costs, the impact of non-automotive inventory charges in the prior year period, lower automotive volumes ~~in our Automotive segment, inflation associated with wages, a non-automotive electronics inventory charge related~~and favorable foreign currency impacts primarily attributable to the ~~exit of the business, the full inclusion of expenses from the acquired businesses and~~Chinese Renminbi. These decreases were partially offset by unfavorable foreign currency impacts primarily attributable to the Euro and the Mexican Peso. ~~These increases were partially offset by lower freight, duties, and material costs, and favorable foreign currency impacts primarily attributable to the Chinese Renminbi.~~

~~Below is a summary of our cost of sales and gross margin, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

Variance Due To:

2023

2022

Favorable /
(Unfavorable)

Automotive Volume

Operational
Performance

FX

Acquisitions and Other

Total

Cost of sales

$
846,815

$
657,492

$
(189,323
)

$
(63,515
)

$
28,417

$
(2,972
)

$
(151,253
)

$
(189,323
)
Gross margin

$
255,328

$
203,842

$
51,486

$
41,848

$
18,499

$
(7,934
)

$
(927
)

$
51,486

Gross margin - Percentage of product revenues

23.2
%

23.7
%

Cost of sales for the nine months ended September 30, 2023 increased 28.8% as compared to the nine months ended September 30, 2022. The increase in cost of sales is primarily due to increased volumes in our Automotive segment, inflation associated with wages and material costs, non-automotive electronics inventory charges related to the exit of the business, the full inclusion of expenses from the acquired businesses and unfavorable foreign currency impacts primarily attributable to the Mexican Peso and the Euro. These increases were partially offset by lower freight and duties costs, and favorable foreign currency impacts primarily attributable to the Chinese Renminbi and the Ukranian Hryvnia.

Net Research and Development Expenses

Below is a summary of our net research and development expenses, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:


	Three Months Ended September 30,									Three Months Ended March 31,
	2023			2022			Favorable / (Unfavorable)			2024			2023			Favorable / (Unfavorable)
Research and development expenses	$	32,298		$	26,841		$	(5,457	)	$	27,742		$	31,749		$	4,007
Reimbursed research and development expenses		(9,148	)		(4,175	)		4,973			(4,997	)		(6,604	)		(1,607	)
Net research and development expenses	$	23,150		$	22,666		$	(484	)	$	22,745		$	25,145		$	2,400
Percentage of product revenues		6.3	%		6.8	%					6.4	%		6.9	%

Net research and development expenses for the three months ended ~~September 30, 2023 increased 2.1%~~March 31, 2024 decreased 9.5% as compared to the three months ended ~~September 30, 2022.~~March 31, 2023. The ~~increase~~decrease in net research and development expenses is primarily related to ~~the full inclusion of net expenses from Alfmeier, partially offset by higher customer reimbursements, excluding those from Alfmeier.~~

~~Below is~~ a ~~summary of our net research and development expenses,~~reduction in ~~thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Research and development expenses

$
94,784

$
75,077

$
(19,707
)
Reimbursed research and development expenses

(21,793
)

(12,652
)

9,141

Net research and development expenses

$
72,991

$
62,425

$
(10,566
)
Percentage of product revenues

6.6
%

7.2
%

~~Net research and development expenses for the nine months ended September 30, 2023 increased 16.9% as compared~~resources allocated to the nine months ended September 30, 2022. The increase in net research and development expenses is primarily related to the full inclusion of net expenses from Alfmeier, increased investments to support new program wins, and lower customer reimbursements, excluding those from Alfmeier.battery performance solutions product category.

Selling, General and Administrative Expenses

Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:


	Three Months Ended September 30,									Three Months Ended March 31,
	2023			2022			Favorable / (Unfavorable)			2024			2023			Favorable / (Unfavorable)
Selling, general and administrative expenses	$	38,220		$	34,859		$	(3,361	)	$	40,721		$	37,042		$	(3,679	)
Percentage of product revenues		10.4	%		10.5	%					11.4	%		10.2	%

Selling, general and administrative expenses for the three months ended ~~September 30, 2023~~March 31, 2024 increased ~~9.6%~~9.9% as compared to the three months ended ~~September 30, 2022.~~March 31, 2023. The increase in selling, general and administrative expenses is primarily related to ~~the full inclusion of expenses from acquired businesses and~~ higher compensation expenses ~~partially offset by lower acquisition costs.~~

~~Below is a summary of our selling, general~~ and ~~administrative expenses,~~increased investment in ~~thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Selling, general and administrative expenses

$
113,680

$
96,109

$
(17,571
)
Percentage of product revenues

10.3
%

11.2
%

Selling, general and administrative expenses for the nine months ended September 30, 2023 increased 18.3% as compared to the nine months ended September 30, 2022. The increase in selling, general and administrative expenses is primarily related to the full inclusion of expenses from acquired businesses and higher compensation expenses, partially offset by lower acquisition costs.

~~Impairment of Goodwill~~

~~There was no impairment of goodwill for the three months ended September 30, 2023 and 2022.~~

~~Below is a summary of our impairment of goodwill, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Impairment of goodwill

$
19,509

$
—

$
(19,509
)

~~Impairment of goodwill for the nine months ended September 30, 2023 related to the recorded Medical reporting unit goodwill impairment.~~information technology.

Restructuring Expenses

Below is a summary of our restructuring expenses, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Restructuring expenses

$
1,099

$
6

$
(1,093
)


	Three Months Ended March 31,
	2024		2023		Favorable / (Unfavorable)
Restructuring expenses	$	7,238	$	1,269	$	(5,969	)

During the three months ended ~~September 30, 2023,~~March 31, 2024, the Company recognized expenses of ~~$1.1~~$6.7 million for employee separation costs and $0$0.5 million for other costs. These restructuring expenses primarily relate to discrete restructuring actions focused on the reduction of global overhead ~~expenses.~~expenses and achieving our Fit-for-Growth 2.0 objectives. See Note 3, “Restructuring,” to the consolidated condensed financial statements included in this Report for additional information.

During the three months ended ~~September 30, 2022,~~March 31, 2023, the Company recognized ~~expenses of~~$1.3 million for employee separation costs and less than $0.1 million for other costs.

~~Below is a summary of our restructuring expenses, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Restructuring expenses

$
3,412

$
561

$
(2,851
)

During the nine months ended September 30, 2023, the Company recognized expenses of $2.6 million for employee separation costs and $0.8 million for other costs. These restructuring expenses primarily relate to discrete restructuring actions focused on the reduction of global overhead expenses.

~~During the nine months ended September 30, 2022, the Company recognized expenses of less than $0.1 million for employee separation costs and $0.5 million for other costs.~~

Interest ~~(Expense) Income,~~Expense, net

~~Below is a summary of our interest (expense) income, net, in thousands, for the three months ended September 30, 2023 and 2022:~~

Three Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Interest (expense) income, net

$
(3,368
)

$
714

$
(4,082
)

Interest expense, net for the three months ended September 30, 2023 increased 571.7% as compared to the three months ended September 30, 2022. The increase is primarily related to less benefit from the change in fair value of the interest rate swap derivative and higher interest rates on the revolving credit agreement, partially offset by decreased interest from a lower balance on the revolving credit agreement during the three months ended September 30, 2023.

Below is a summary of our interest expense, net, in thousands, for the ~~nine~~three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Interest expense, net

$
(9,444
)

$
(1,285
)

$
(8,159
)


	Three Months Ended March 31,
	2024			2023			Favorable / (Unfavorable)
Interest expense, net	$	(3,244	)	$	(4,144	)	$	900

Interest expense, net for the ~~nine~~three months ended ~~September 30, 2023 increased 634.9%~~March 31, 2024 decreased 21.7% as compared to the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023. The ~~increase~~decrease is primarily related to ~~less~~a benefit from the change in fair value of the interest rate swap derivative, ~~and~~partially offset by higher interest rates on outstanding borrowings under the revolving credit agreement, partially offset by decreased interest from a lower balance on the revolving credit agreement during the nine months ended September 30, 2023. See Note 6, "Debt," to the consolidated condensed financial statements included in this Report for additional information.Revolving Credit Facility.

Foreign Currency Gain (Loss)

Below is a summary of our foreign currency gain (loss), in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Foreign currency gain (loss)

$
2,107

$
(8,285
)

$
10,392


	Three Months Ended March 31,
	2024		2023			Favorable / (Unfavorable)
Foreign currency gain (loss)	$	2,549	$	(2,069	)	$	4,618

Foreign currency gain for the three months ended ~~September 30, 2023~~March 31, 2024 included net realized foreign currency gain of ~~$1.2~~$0.7 million and net unrealized foreign currency gain of ~~$0.9~~$1.9 million.

Foreign currency loss for the three months ended ~~September 30, 2022~~March 31, 2023 primarily included net realized foreign currency ~~loss~~gain of ~~$3.0~~$3.8 million and net unrealized foreign currency loss of ~~$5.3 million.~~

~~Below is a summary of our foreign currency gain (loss), in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Foreign currency gain (loss)

$
384

$
(1,516
)

$
1,900

~~Foreign currency gain for the nine months ended September 30, 2023 included net realized foreign currency gain of $4.6 million and net unrealized foreign currency loss of $4.2 million.~~

~~Foreign currency loss for the nine months ended September 30, 2022 primarily included net realized foreign currency loss of $2.6 million and net unrealized foreign currency gain of $1.1~~$5.9 million.

Other Income

Below is a summary of our other income, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Other income

$
272

$
361

$
(89
)


	Three Months Ended March 31,
	2024		2023		Favorable / (Unfavorable)
Other income	$	973	$	230	$	743

Other income for the three months ended ~~September 30, 2023 decreased~~March 31, 2024 increased as compared to the three months ended ~~September 30, 2022. The decrease in Other income is due to a decrease in miscellaneous income.~~

~~Below is a summary of our other income, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Other income

$
1,058

$
698

$
360

~~Other income for the nine months ended September 30, 2023 increased as compared to the nine months ended September 30, 2022.~~March 31, 2023. The increase in ~~Other~~other income is due to an increase in ~~miscellaneous income.~~the fair value of our investment in Carrar due to observable transactions.

Income Tax Expense

Below is a summary of our income tax expense, in thousands, for the three months ended ~~September 30, 2023~~March 31, 2024 and ~~2022:~~2023:

Three Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Income tax expense

$
6,908

$
5,784

$
(1,124
)


	Three Months Ended March 31,
	2024		2023		Favorable / (Unfavorable)
Income tax expense	$	3,542	$	3,728	$	186

Income tax expense was ~~$6.9~~$3.5 million for the three months ended ~~September 30,~~March 31, 2024, on earnings before income tax of $18.3 million, representing an effective tax rate of 19.3%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of a one-time benefit related to the Alfmeier acquisition, partially offset by income taxes on foreign earnings taxed at rates varying from the U.S. Federal statutory rate and the unfavorable impact of the global intangible low-tax income (“GILTI”).

Income tax expense was $3.7 million for the three months ended March 31, 2023 on earnings before income tax of ~~$22.8~~$11.7 million, representing an effective tax rate of ~~30.4%~~31.9%. The tax amount included the effect of the settlement and closure of a multi-year state audit of $0.5 million. Adjusted for the audit impacts, the effective rate was 28.0%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. ~~statutory rate and the unfavorable impact of the global intangible low-tax income (“GILTI”), partially offset by the impact of the release of accruals for uncertain tax positions.~~

Income tax expense was $5.8 million for the three months ended September 30, 2022 on earnings before income tax of $15.6 million representing an effective tax rate of 37.1%. The effective tax rate differed from the U.S. Federal ~~statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S.~~ statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of ~~certain favorable tax effects on equity vesting.~~

~~Below is a summary of our income tax expense, in thousands, for the nine months ended September 30, 2023 and 2022:~~

Nine Months Ended September 30,

2023

2022

Favorable /
(Unfavorable)

Income tax expense

$
15,478

$
13,998

$
(1,480
)

Income tax expense was $15.5 million for the nine months ended September 30, 2023, on earnings before income tax of $37.7 million, representing an effective tax rate of 41.0%. The pre-tax earnings included the effect of an impairment loss of $19.5 million with a tax benefit of $2.5 million. Adjusted for the impairment impacts, the effective rate was 31.0%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate and the unfavorable impact of the GILTI, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects ~~of equity vesting and the release of accruals for uncertain tax positions.~~

~~Income tax expense was $14.0 million for the nine months ended September 30, 2022~~ on earnings before income tax of $42.6 million representing an effective tax rate of 32.8%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, and the quarterly accrual for uncertain tax positions, partially offset by the impact of certain favorable tax effects of equitystock compensation vesting.

3429

Liquidity and Capital Resources

Overview

Our primary sources of liquidity and capital resources are cash flows from operations and borrowings available under our Second Amended and Restated Credit Agreement. Our cash requirements consist principally of working capital, capital expenditures, research and development, operating lease payments, income tax payments and general corporate purposes. We generally reinvest available cash flows from operations into our business, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition, disposition, exits, and investment opportunities that will enhance our business strategies.

As of ~~September 30, 2023,~~March 31, 2024, the Company had ~~$154.4~~$125.1 million of cash and cash equivalents and ~~$293.0~~$278.0 million of availability under our Second Amended and Restated Credit Agreement. We may issue debt or equity securities, which may provide an additional source of liquidity. However, there can be no assurance equity or debt financing will be available to us when we need it or, if available, the terms will be satisfactory to us and not dilutive to our then-current shareholders.

We continue to expect to be able to move funds between different countries to manage our global liquidity needs without material adverse tax implications, subject to current monetary policies and the terms of the Second Amended and Restated Credit Agreement. We utilize a combination of strategies, including dividends, cash pooling arrangements, intercompany loan repayments and other distributions and advances to provide the funds necessary to meet our global liquidity needs. There are no significant restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Gentherm Incorporated. As of ~~September 30, 2023,~~March 31, 2024, the Company’s cash and cash equivalents held by our non-U.S. subsidiaries totaled ~~approximately $114.7~~$88.1 million. If additional non-U.S. cash was needed for our U.S. operations, we may be required to accrue and pay withholding if we were to distribute such funds from non-U.S. subsidiaries to the U.S.; however, based on our current liquidity needs and strategies, we do not anticipate a need to accrue and pay such additional amounts.

We currently believe that our cash and cash equivalents, borrowings available under our Second Amended and Restated Credit Agreement and receivables factoring arrangements, and cash flows from operations will be adequate to meet anticipated cash requirements for at least the next twelve months and the foreseeable future.

Cash and Cash Flows

The following table represents our cash and cash equivalents, in thousands:


	Nine Months Ended September 30,						Three Months Ended March 31,
	2023			2022			2024			2023
Cash and cash equivalents at beginning of period	$	153,891		$	190,606		$	149,673		$	153,891
Net cash provided by operating activities		80,042			12,957
Net cash (used in) provided by operating activities								(10,322	)		25,109
Net cash used in investing activities		(16,945	)		(247,841	)		(8,831	)		(2,549	)
Net cash (used in) provided by financing activities		(60,751	)		191,582
Net cash used in financing activities								(1,534	)		(12,965	)
Foreign currency effect on cash and cash equivalents		(1,883	)		(8,141	)		(3,879	)		3,144
Cash and cash equivalents at end of period		154,354			139,163		$	125,107		$	166,630

Cash Flows From Operating Activities

Net cash ~~provided by~~used in operating activities totaled ~~$80.0~~$10.3 million during the ~~nine~~three months ended ~~September 30, 2023~~March 31, 2024 primarily reflecting $42.0 million related to changes in assets and liabilities, non-cash charges of $0.2 million for deferred income taxes and $0.8 million of other, partially offset by net income of ~~$22.3~~$14.8 million, ~~$19.5 million for non-cash goodwill impairment, $47.9~~$17.7 million for non-cash charges for depreciation, amortization, stock based compensation and loss on disposition of property and non-cash charges of ~~$6.6~~$0.3 million for inventory ~~provisions, partially offset by $13.2 million related to changes in assets and liabilities, and non-cash charges of $3.0 million for deferred income taxes.~~provisions.

Cash Flows From Investing Activities

Net cash used in investing activities was ~~$16.9~~$8.8 million during the ~~nine~~three months ended ~~September 30, 2023,~~March 31, 2024, reflecting purchases of property and equipment of ~~$26.5~~$11.3 million and investments in technology companies of ~~$0.6~~$0.2 million, partially offset by proceeds from deferred purchase price of factored receivables of ~~$10.1~~$2.7 million.

3530

Cash Flows From Financing Activities

Net cash used in financing activities was ~~$60.8~~$1.5 million during the ~~nine~~three months ended ~~September 30, 2023,~~March 31, 2024, reflecting ~~$31.0 million paid to repurchase common stock, $27.2~~$10.3 million of debt repayments and ~~$2.8~~$2.0 million paid for employee taxes related to the net settlement of restricted stock units that vested during the year, partially offset by the borrowing on debt of $10.0 million and the proceeds from the exercise of Common Stock options totaling ~~$0.3~~$0.8 million.

Debt

The following table summarizes the Company’s debt, in thousands, as of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022:~~2023:


	September 30, 2023						December 31, 2022						March 31, 2024						December 31, 2023
	Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance			Interest Rate			Principal Balance
Credit Agreement:
Revolving Credit Facility (U.S. Dollar denominations)		6.79	%	$	207,000			5.80	%	$	232,000			6.80	%	$	222,000			6.58	%	$	222,000
Other loans		3.90	%		247		3.89% - 5.21%				2,011			—			—			3.90	%		233
Finance leases		3.54	%		675			3.57	%		1,085			3.51	%		497			3.53	%		605
Total debt					207,922						235,096						222,497						222,838
Current maturities					(620	)					(2,443	)					(324	)					(621	)
Long-term debt, less current maturities				$	207,302					$	232,653					$	222,173					$	222,217

Credit Agreement

Gentherm, together with certain of its subsidiaries, maintain a revolving credit note (the “Revolving Credit Facility”) under its Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Second Amended and Restated Credit Agreement was entered into on June 10, 2022 and amended and restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement has a maximum borrowing capacity of $500 million and matures on June 10, 2027. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. As of ~~September 30, 2023,~~March 31, 2024, the Company was in compliance, in all material respects, with the terms of the Second Amended and Restated Credit Agreement.

Finance Leases

As of ~~September 30, 2023~~March 31, 2024 and December 31, ~~2022,~~2023, there was ~~$0.7~~$0.5 million and ~~$1.1~~$0.6 million, respectively, of outstanding finance leases.

Other Sources of Liquidity

The Company is party to receivable factoring agreements with unrelated third parties under which we can sell receivables for certain account debtors, on a revolving basis, subject to outstanding balances and concentration limits. The receivable factoring agreements are transferred in their entirety to the acquiring entities and are accounted for as a sale. Some of the agreements, including those assumed through the acquisition of Alfmeier, have deferred purchase price arrangements. As of ~~September 30, 2023,~~March 31, 2024, there were ~~$1.2~~$7.4 million available under the receivable factoring ~~agreement.~~agreements.

Material Cash Requirements

The Company continues to enter into agreements with suppliers to reserve the right to purchase certain semiconductor chips over periods of 12-24 months. As of September 30, 2023, the Company’s total commitments for these semiconductor chip agreements was $25.6 million. See Note 7, “Commitments and Contingencies” to the consolidated condensed financial statements included in this Report for additional information.

In September 2023, the Company committed to a restructuring plan to improve the Company’s manufacturing productivity and rationalize its footprint. As of ~~September 30, 2023,~~March 31, 2024, the Company expects to incur total costs of between ~~$14~~$12 million and ~~$18~~$16 million, of which between ~~$14~~$11 million and ~~$17~~$15 million are expected to be cash expenditures. The Company has recorded $1.7 million of restructuring expenses since the inception of this program as of March 31, 2024. See Note 3, “Restructuring, ~~and Impairments”~~” to the consolidated condensed financial statements included in this Report for additional information.

Except as described above, there have been no material changes in our cash requirements since December 31, ~~2022,~~2023, the end of fiscal year ~~2022.~~2023. See Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, ~~2022~~2023 for additional information regarding our material cash requirements.

Effects of Inflation

The automotive component supply industry has historically been subject to inflationary pressures with respect to materials and labor. ~~Beginning in~~Since 2021, ~~and continuing through 2023,~~ the automotive industry has experienced ~~inflationary cost increases~~a period of significant volatility in the costs of certain materials and components, labor and transportation. Although supply chain conditions have steadily improved and certain inflationary pressures have moderated, rising costs of materials, labor, equipment and other inputs used to manufacture and sell our products, including freight and logistics costs, have impacted, and may in the future impact, operating costs and operating results. These higher costs and cost increases due to inflation are expected to continue for the foreseeable future as demand remains elevated and supply remains constrained. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and transportation costs through sourcing and manufacturing efficiencies where possible, these strategies together with commercial negotiations with Gentherm's customers and suppliers have not fully offset to date and may not fully offset our future cost increases. Such inflationary cost increase may increase the cash required to fund our operations by a material amount.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting ~~Policies”~~Policies,” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2022.~~2023. There have been no significant changes in our critical accounting policies or critical accounting estimates during the three months ended ~~September 30, 2023.~~March 31, 2024. We are not presently aware of any events or circumstances that would require us to update our estimates, assumptions or revise the carrying value of our assets or liabilities, except for the impairment of the Medical segment goodwill, which was assessed in the second quarter of 2023. See Note 3, “Restructuring and Impairments” to the consolidated condensed financial statements included in this Report for additional information.liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

~~Recent Accounting Pronouncements~~

~~There are no new accounting pronouncements applicable to the Company as of September 30, 2023.~~32

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to the Company's debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, acquisitions denominated in foreign currencies, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts that can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to ~~Accumulated~~accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in ~~Accumulated~~accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to ~~Cost~~cost of sales, and the ineffective portion of interest rate swaps, if any, to ~~Interest~~interest expense, net in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in ~~Net~~net cash (used in) provided by ~~(used in)~~ operating activities in the consolidated condensed statements of cash flows.

Information related to the fair values of all derivative instruments in ~~our~~the consolidated condensed balance sheet as of ~~September 30, 2023~~March 31, 2024 is set forth in Note 9,10, “Financial Instruments” in the consolidated condensed financial statements included in this Report.

Interest Rate Sensitivity

The table below presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations, excluding finance leases. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency.


	Expected Maturity Date																			Expected Maturity Date
	2023			2024		2025		2026		2027			2028		Total			Fair Value		2024		2025		2026		2027			2028		2029		Total			Fair Value
Liabilities
Long-Term Debt:
Variable rate	$	—		$	—	$	—	$	—	$	207,000		$	—	$	207,000		$	207,000	$	—	$	—	$	—	$	222,000		$	—	$	—	$	222,000		$	222,000
Variable interest rate as of September 30, 2023											6.79	%				6.79	%
Fixed rate	$	247		$	—	$	—	$	—	$	—		$	—	$	247		$	—
Fixed interest rate		3.90	%													3.90	%
Variable interest rate as of March 31, 2024																											6.80	%						6.80	%

Based on the amounts outstanding as of ~~September 30, 2023,~~March 31, 2024, a hypothetical 100 basis point change (increase or decrease) in interest rates would impact annual interest expense by ~~$2.1~~$2.2 million. To hedge the Company's exposure to interest payment fluctuations on a portion of these borrowings, we entered into a floating-to-fixed interest rate swap agreement with a notional amount of $100.0 million.

3833

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency ~~forward~~ exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected ~~(contractual)~~ maturity dates for each type of foreign currency ~~forward~~ exchange agreement. These notional amounts generally are used to calculate the ~~contractual~~ payments to be exchanged under the contract.


	Expected Maturity or Transaction Date										Expected Maturity or Transaction Date
Anticipated Transactions and Related Derivatives	2023		2024		2025		Total		Fair Value		2024		2025		Total		Fair Value
USD Functional Currency
Forward Exchange Agreements:
Exchange Agreements:
(Receive MXN / Pay USD)
Total contract amount	$	14,824	$	59,298	$	29,649	$	103,771	$	6,706	$	44,473	$	29,649	$	74,122	$	9,113
Average contract rate		19.23		19.23		19.23		19.23				19.23		19.23

The table below presents the potential gain and loss in fair value for the foreign currency derivative contracts from a hypothetical 10% change in quoted currency exchange rates.


	September 30, 2023				December 31, 2022				March 31, 2024				December 31, 2023
Exchange Rate Sensitivity	Potential loss in fair value		Potential gain in fair value		Potential loss in fair value		Potential gain in fair value		Potential loss in fair value		Potential gain in fair value		Potential loss in fair value		Potential gain in fair value
Forward Exchange Agreement:(Receive MXN / Pay USD)	$	5,978	$	10,677	$	3,999	$	4,888
Exchange Agreement:(Receive MXN / Pay USD)									$	6,531	$	8,682	$	7,179	$	9,798

3934

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of ~~September 30, 2023.~~March 31, 2024. As defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), disclosure controls and procedures are controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported on a timely basis, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of ~~September 30, 2023.~~March 31, 2024.

(b) Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the three months ended ~~September 30, 2023~~March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

4035

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of business, however there iswas no material pending litigation to which we are a party and no material legal proceeding was terminated, settled or otherwise resolved during the three months ended ~~September 30, 2023.~~March 31, 2024.

ITEM 1A. RISK FACTORS

The Company’s risk factors have not materially changed from those previously disclosed in Part 1, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2022.~~2023. You should carefully consider the risks and uncertainties described therein.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities During ~~Third~~First Quarter ~~2023~~2024

Period

(a)
Total Number
of Shares
Purchased

(b)
Average Price
Paid Per Share

(c)
Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs

(d)
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1)

July 1, 2023 to July 31, 2023

—

$
—

—

$
—

August 1, 2023 to August 31, 2023

—

$
—

—

$
—

September 1, 2023 to September 30, 2023

195,062

$
56.91

195,062

$
98,906,454


Period	(a) Total Number of Shares Purchased		(b) Average Price Paid Per Share		(c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs		(d) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
January 1, 2024 to January 31, 2024		—	$	—		—	$	37,490,518
February 1, 2024 to February 29, 2024		—	$	—		—	$	37,490,518
March 1, 2024 to March 31, 2024		—	$	—		—	$	37,490,518

~~(1)~~

~~In December 2020,~~For further information regarding the ~~Board~~ASR Agreement and the final settlement date that is scheduled to occur in the second quarter of ~~Directors authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under~~2024, see Note 12, "Equity," to the ~~2020 Stock Repurchase Program,~~notes to the ~~Company is authorized to repurchase up to $150.0 million of its issued and outstanding common stock over a three-year period, expiring December 15, 2023. The authorization of~~consolidated condensed financial statements included in this stock repurchase program does not require that the Company repurchase any specific dollar value or number of shares and may be modified, extended or terminated by the Company’s Board of Directors at any time.Report.

ITEM 5. OTHER INFORMATION

Trading Plans – Directors and Section 16 Officers

During the three months ended ~~September 30, 2023,~~March 31, 2024, none of the Company's directors or Section 16 officers adopted or terminated (i) any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or (ii) any non-Rule 10b5-1 trading arrangement.

4136

ITEM 6. EXHIBITS

Exhibits to this Report are as follows:

Incorporated by Reference
Exhibit
Number

Exhibit Description
Filed
/Furnished
Herewith
Form

Period
Ending

Exhibit /
Appendix Number

Filing Date
  3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18
  3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16
  10.1*

Amendment to Offer Letter between Gentherm Incorporated and Helen Xu, dated as of August 21, 2023

X

  31.1
Section 302 Certification – CEO

X

  31.2
Section 302 Certification – CFO

X

  32.1**
Section 906 Certification – CEO

X

  32.2**
Section 906 Certification – CFO

X

101.INS
Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

X

101.SCH
Inline XBRL Taxonomy Extension Schema Document.

X

101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.

X

101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.

X

104

Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)

X

Incorporated by Reference

Exhibit

Number

Exhibit Description

Filed

/Furnished

Herewith

Form

Period

Ending

Exhibit /
Appendix Number

Filing Date

3.1

Second Amended and Restated Articles of Incorporation of Gentherm Incorporated

8-K

3.2

3/5/18

3.2

Amended and Restated Bylaws of Gentherm Incorporated

8-K

3.1

5/26/16

10.1*

Offer Letter between Gentherm Incorporated and Vishnu Sundaram, dated as of August 31, 2023

10.2*

Amendment to Offer Letter between Gentherm Incorporated and Vishnu Sundaram, dated as of February 5, 2024

31.1

Section 302 Certification – CEO

31.2

Section 302 Certification – CFO

32.1**

Section 906 Certification – CEO

32.2**

Section 906 Certification – CFO

101.INS

Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

104

Cover Page Interactive Date File – the cover page XBRL tags are embedded within the Inline XBRL document

* Indicates management contract or compensatory plan.

** Documents are furnished not filed.

4237

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Gentherm Incorporated

	/s/ PHILLIP EYLER
	Phillip Eyler
	President and Chief Executive Officer
	(Principal Executive Officer)

	Date: ~~October 26, 2023~~April 30, 2024


	/s/ MATTEO ANVERSA
	Matteo Anversa
	Executive Vice President, Chief Financial Officer and Treasurer
	(Principal Financial Officer)

	Date: ~~October 26, 2023~~April 30, 2024

4338


	Initial Allocation as of August 1, 2022			Measurement Period Adjustments			Final Allocation
Purchase price, cash consideration, net of cash acquired	$	164,887		$	5,813		$	170,700
								—
Accounts receivable		24,988			(121	)		24,867
Inventory		36,026			417			36,443
Prepaid expenses and other assets		20,920			(74	)		20,846
Operating lease right-of-use assets		4,608			—			4,608
Property and equipment		89,942			1,242			91,184
Other intangible assets		22,668			8,791			31,459
Goodwill		43,678			(9,707	)		33,971
Assumed liabilities		(55,994	)		975			(55,019	)
Deferred tax liabilities		(21,949	)		4,290			(17,659	)
Net assets acquired	$	164,887		$	5,813		$	170,700


	Final Fair Value		Weighted Average Life (in years)
Definite-lived:
Customer related	$	19,812		14
Technology		11,647		9
Total	$	31,459


	Three Months Ended September 30, 2022		Nine Months Ended September 30, 2022
Product revenues	$	352,877	$	1,004,974
Net income		9,033		21,330


	Initial Allocation as of July 13, 2022			Measurement Period Adjustments			Final Allocation
Purchase price, cash consideration, net of cash acquired	$	35,048		$	—		$	35,048
								—
Accounts receivable		746			(124	)		622
Inventory		1,942			(177	)		1,765
Prepaid expenses and other assets		152			22			174
Operating lease right-of-use assets		841			—			841
Property and equipment		684			—			684
Other intangible assets		19,094			965			20,059
Goodwill		22,995			(3,464	)		19,531
Assumed liabilities		(2,799	)		(515	)		(3,314	)
Deferred tax liabilities		(8,607	)		3,293			(5,314	)
Net assets acquired	$	35,048		$	—		$	35,048